Evaluation Of Cationic Polymer Vectors For Non-viral Gene Delivery by Güngördü, Hatice İmran
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
M.Sc. THESIS 
JUNE 2012 
 
EVALUATION OF CATIONIC POLYMER VECTORS FOR NON-VIRAL 
GENE DELIVERY 
 
Hatice İmran GÜNGÖRDÜ 
Department of Chemistry 
 
Chemistry Programme 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
   
     
JUNE 2012 
ISTANBUL TECHNICAL UNIVERSITY  GRADUATE SCHOOL OF SCIENCE 
ENGINEERING AND TECHNOLOGY 
EVALUATION OF CATIONIC POLYMER VECTORS FOR NON-VIRAL 
GENE DELIVERY 
 
M.Sc. THESIS 
Hatice İmran GÜNGÖRDÜ 
 (509101061) 
Department of Chemistry 
 
Chemistry Programme 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Thesis Advisor: Prof. Dr. Gülaçtı TOPÇU 
   
     
HAZİRAN 2012 
İSTANBUL TEKNİK ÜNİVERSİTESİ  FEN BİLİMLERİ ENSTİTÜSÜ 
KATYONİK POLİMERLERİN GEN TAŞIYICI SİSTEMLERİ OLARAK 
DEĞERLENDİRİLMESİ 
YÜKSEK LİSANS TEZİ 
Hatice İmran GÜNGÖRDÜ 
(509101061) 
Kimya Anabilim Dalı 
 
Kimya Programı 
 
 
 
Anabilim Dalı : Herhangi Mühendislik, Bilim 
Programı : Herhangi Program 
 
Tez Danışmanı: Prof. Dr. Gülaçtı TOPÇU 
  
 
v 
 
  
Thesis Advisor :  Prof. Dr. Gülaçtı TOPÇU    
 İstanbul Technical University  
Jury Members :  Prof. Dr. Bahire Filiz ŞENKAL 
                         İstanbul Technical University 
Prof. Dr. Jülide AKBUGA   
Marmara University 
Hatice İmran GÜNGÖRDÜ, a M.Sc. student of ITU Graduate School of Science 
Engineering and Technology student ID 509101061, successfully defended the 
thesis entitled “EVALUATION OF CATIONIC POLYMER VECTORS FOR 
NON-VIRAL GENE DELIVERY”, which she prepared after fulfilling the 
requirements specified in the associated legislations, before the jury whose signatures 
are below. 
 
 
Date of Submission : 04 May 2012 
Date of Defense :  08 June 2012 
 
 
 
 
 
vi 
 
  
vii 
 
 
 
 
Dedicated to my beloved family and  
everyone in pursuit of his curiosity,  
viii 
 
ix 
 
FOREWORD 
First of all, I am greatly indebted to my thesis advisor in Istanbul Technical 
University, Prof. Dr. Gülaçtı Topçu who has inspired me with her hard-working and 
enthusiastic personality as a scientist. She has always supported me about my area of 
interest and rendered the possibility for an international research experience for me. 
 
I feel honored to express my gratitude to my thesis advisor in Ghent University, Prof. 
Dr. Kevin Braeckmans as well as his colleagues Prof. Dr. Stefaan De Smedt and 
Prof. Dr. Jo Demeester for giving me the opportunity to pursue my thesis study as a 
member of their interdisciplinary and extraordinary group.  
 
My very sincere thanks to my supervisor Thomas Martens for his guidance, 
encouragements and teaching me all the skills that I needed to work on this project 
independently. As a chemist, gene therapy was a brand new research area for me. 
During my thesis studies, he has shared all his knowledge and experience with me 
and expedited my adaptation to this research. 
 
Despite my short stay in Ghent, I had the chance to collaborate with two different 
groups. I would like to mention my thanks to Prof. Dr. Johan Engbersen and Dr. 
Marc Ankone from University of Twente and Prof. Dr. Peter Dubruel and Dr. 
Kehinde Adesanya from Ghent University for their kind collaborations and helps for 
polymer synthesis. 
 
I am also thankful to everyone in “Laboratory of Biochemistry and Physical 
Pharmacy”, especially Dr. Joanna Rejman, Dr. Katrien Remaut and Dr. Bart Lucas, 
for their warmest welcome and sharing their experience whenever I needed. 
 
I cannot forget to thank the dear people, both my lab-mates and home-mates, that 
beautiful city of Ghent brought to me during those unforgettable days of my Erasmus 
experience. I would also like to say my warmest thanks to my lab-mates and 
colleagues in İTÜ, Dr. Fatemeh Bahadori, Demet, Burcu, Tuba, Seda, Anıl, Tayyibe, 
and Mervenur for their moral support during my studies. 
 
Finally, I owe the greatest gratitude to my beloved family who stands by me 
unconditionally with full support and advice all the time. 
  
 
 
 
 
June 2012 
 
Hatice İmran GÜNGÖRDÜ 
(Chemist) 
 
 
x 
 
 
 
 
 
 
 
 
 
  
xi 
 
 
TABLE OF CONTENTS 
Page 
FOREWORD ............................................................................................................. ix 
TABLE OF CONTENTS .......................................................................................... xi 
ABBREVIATIONS .................................................................................................. xv 
LIST OF TABLES ................................................................................................. xvii 
LIST OF FIGURES ................................................................................................ xix 
SUMMARY ........................................................................................................... xxiii 
ÖZET ....................................................................................................................... xxv 
1. INTRODUCTION .................................................................................................. 1 
1.1 Purpose of The Thesis ........................................................................................ 1 
1.2 Outline of The Thesis ......................................................................................... 2 
2. BASICS OF CELL BIOLOGY ............................................................................. 3 
2.1 The Cell .............................................................................................................. 3 
2.2 Cell (Plasma) Membrane .................................................................................... 3 
2.3 Cellular Entry of Extracellular Material ............................................................. 5 
2.3.1 Endocytosis and endosomes ........................................................................ 5 
2.3.2 Lysosome .................................................................................................... 7 
2.4 Intracellular Environment .................................................................................. 8 
2.4.1 Cytoplasm and cytosol ................................................................................ 8 
2.4.2 Cytoskeleton ................................................................................................ 8 
2.5 Cell Nucleus ....................................................................................................... 9 
2.5.1 Function ...................................................................................................... 9 
2.5.2 Nuclear envelope and pores ........................................................................ 9 
2.6 Gene Expression ............................................................................................... 10 
2.6.1 Transcription ............................................................................................. 10 
2.6.2 Translation ................................................................................................ 11 
3. GENE THERAPY ................................................................................................ 13 
3.1 A Brief History of Gene Therapy ..................................................................... 13 
3.2 Barriers for Gene Delivery ............................................................................... 15 
3.2.1 Stability in the extracellular environment ................................................. 15 
3.2.2 Cellular attachment and adhesion ............................................................. 16 
3.2.3 Cellular uptake .......................................................................................... 17 
3.2.4 Endosomal escape ..................................................................................... 18 
3.2.5 Cellular translocation to the nucleus ......................................................... 19 
3.2.6 Nuclear import  ......................................................................................... 20 
3.3 Methods for Gene Delivery .............................................................................. 21 
3.3.1 Physical methods ....................................................................................... 21 
3.3.1.1 Gene gun ............................................................................................ 21 
3.3.1.2 Electroporation ................................................................................... 21 
3.3.1.3 Gene transfer by ultrasound radiation   .............................................. 22 
3.3.2 Viral vectors .............................................................................................. 23 
xii 
 
3.3.2.1 Adeno-associated virus ...................................................................... 23 
3.3.3 Non-viral vectors ....................................................................................... 23 
3.3.3.1 Lipid-based gene delivery systems .................................................... 24 
3.3.3.2 Polymer-based gene delivery systems ................................................ 25 
4. MATERIALS AND METHODS ......................................................................... 29 
4.1 Polymer Synthesis ............................................................................................ 29 
4.1.1 Synthesis of pDMAEMA by radicalic polymerization ............................. 29 
4.1.2 Synthesis of SS-PAAs by Michael-type polyaddition .............................. 34 
4.2 Cell Culture ...................................................................................................... 37 
4.2.1 Materials .................................................................................................... 37 
4.2.2 Methods used in cell culture...................................................................... 37 
4.3 Nucleic acids used in this study........................................................................ 38 
4.3.1 pGL4.13 plasmid ....................................................................................... 38 
4.3.2 gWiz™-GFP plasmid ................................................................................ 39 
4.3.3 YOYO
®
-1 iodide labelled pGL4.13 plasmid ............................................ 40 
4.4 Preparation and Physicochemical Characterization of Polyplexes .................. 40 
4.4.1 Dynamic light scattering ........................................................................... 40 
4.4.1.1 Theory and working principles .......................................................... 40 
4.4.1.2 Particle size and surface charge measurements .................................. 43 
4.4.2 Preparation of polyplexes .......................................................................... 43 
4.4.2.1 pDMAEMA polyplexes ..................................................................... 44 
4.4.2.2 SS-PAA polyplexes ............................................................................ 46 
4.4.3 Agarose gel electrophoresis ...................................................................... 47 
4.4.3.1 Principles ............................................................................................ 47 
4.4.3.2 Experimental part ............................................................................... 48 
4.5 In vitro Biological Evaluation of Polyplexes ................................................... 49 
4.5.1 Flow cytometry ......................................................................................... 49 
4.5.1.1 Principles ............................................................................................ 49 
4.5.2 Uptake and transfection efficiency studies................................................ 50 
4.5.3 Cell viability .............................................................................................. 51 
4.5.3.1 MTT assay .......................................................................................... 51 
4.5.3.2 Experimental ...................................................................................... 52 
5. RESULTS AND DISCUSSION........................................................................... 53 
5.1 Polymer Synthesis ............................................................................................ 53 
5.1.1 Characterization of polymers .................................................................... 53 
5.1.1.1 pDMAEMA ........................................................................................ 53 
5.1.1.2 SS-PAAs............................................................................................. 53 
5.2 pDMAEMA polyplexes.................................................................................... 58 
5.2.1 Physicochemical characterization ............................................................. 58 
5.2.1.1 Particle size and surface charge measurements .................................. 58 
5.2.1.2 pDNA complexation efficiency ......................................................... 59 
5.2.2 In vitro biological evaluation .................................................................... 61 
5.2.2.1 Uptake efficiency ............................................................................... 61 
5.2.2.2 Transfection efficiency ....................................................................... 62 
5.2.2.3 Cell viability ....................................................................................... 62 
5.2.3 Discussion ................................................................................................. 63 
5.3 SS-PAA Polyplexes .......................................................................................... 66 
5.3.1 p(CBA-ABOL) polyplexes ....................................................................... 67 
5.3.1.1 Physicochemical characterization ...................................................... 67 
5.3.1.2 In vitro biological evaluation  ............................................................ 70 
xiii 
 
    5.3.1.3 Discussion .......................................................................................... 72 
5.3.2 p(CBA-ABOL/DMEDA/PEG) polyplexes ............................................... 74 
5.3.2.1 Physicochemical characterization ...................................................... 75 
5.3.2.2 In vitro biological evaluation  ............................................................ 76 
    5.3.2.3 Discussion .......................................................................................... 79 
5.3.3 HA-coated p(CBA-ABOL) polyplexes ..................................................... 80 
5.3.3.1 Physicochemical characterization ...................................................... 80 
5.3.3.2 In vitro biological evaluation  ............................................................ 83 
    5.3.3.3 Discussion .......................................................................................... 86 
5.3.4 p(CBA-HIS) polyplexes ............................................................................ 87 
5.3.4.1 Physicochemical characterization ...................................................... 87 
5.3.4.2 In vitro biological evaluation  ............................................................ 90 
        5.3.4.3 Discussion .......................................................................................... 93 
6. CONCLUSION ..................................................................................................... 95 
REFERENCES ......................................................................................................... 97 
APPENDICES ........................................................................................................ 109 
APPENDIX A. ..................................................................................................... 111 
CURRICULUM VITAE ........................................................................................ 113 
 
 
 
 
 
  
xiv 
 
 
 
 
 
 
 
 
 
xv 
 
 
ABBREVIATIONS 
ABOL : 4-aminobutan-1-ol 
AIDS : Acquired immunodeficiency syndrome 
App : Appendix 
APS : Ammonium persulfate 
CBA : N,N′-cystaminebisacrylamide 
CF : Cystic Fibrosis 
DLS : Dynamic Light Scattering 
DMAEMA : Dimethylaminoethyl methacrylate 
DMEDA : N, N’-dimethyl ethyl-1,2-diamine 
DMEM : Dulbecco's modified Eagle's medium 
DNA : Deoxyribonucleic acid 
DTT : Dithiothreitol  
ECM : Extracellular matrix  
FC : Flow Cytometry 
GAG : Glycosaminoglycan 
GFP : Green Fluorescent Protein 
GPC : Gel Permeation Chromatography 
HA : Hyaluronic acid (Hyaluronan) 
HEPES : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIS : Histamine 
HS : Heparan Sulphate 
HSPG : Heparan sulphate proteoglycan 
IF : Integrated filament 
kDa : Kilodalton 
LF : Lipofectamine™ 2000 Reagent   
MF : Microfilament 
mRNA : Messenger Ribonucleic Acid 
MT : Microtubule 
MTT             : 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Mw : Molecular weight 
MWCO : Molecular weight cut-off 
NLS : Nuclear localization signal 
NMR : Nuclear Magnetic Resonance 
NPC : Nuclear pore complex 
OTC : Ornithine transcarbamylase   
P/S : Penicillin-Streptomycin 
PAA : Poly(amidoamine) 
PAMAM : Poly(amidoamine) 
PBS : Phosphate buffer saline 
pDI : Polydispersity index 
pDNA : Plasmid DNA 
PEG : Poly(ethylene glycol) 
xvi 
 
PEI : Poly(ethylene imine) 
PG : Proteoglycan 
pHPMA : Poly(hydroxypropyl methacrylate) 
PLL : Poly(L-lysine) 
Pplx : Polyplex 
PS : Polstyrene 
RGD : Arginine-glycine-aspartate   
RNA : Ribonucleic acid 
RPE : Retinal Pigment Epithelium 
RT : Room Temperature 
SCID : Severe combined immunodeficiency  
SS-PAA : Linear, disulfide-containing poly(amidoamine) 
TBE : Tris-base boric acid EDTA 
TMS : Tetramethylsilane 
US : Ultrasound 
 
 
 
 
 
  
xvii 
 
 
LIST OF TABLES 
Page 
Table 5.1 : The amounts of pDMAEMA polymer and pDNA which was used to 
obtained desired polymer/pDNA (w/w) ratios ........................................ 59 
Table 5.2 : Illustration of average size, pDI and charge values for pDMAEMA 
polyplexes................................................................................................ 59  
Table 5.3 : The amounts of p(CBA-ABOL) polymer and pDNA which was used to 
obtain desired polymer/pDNA (w/w) ratios. The polyplexes were 
prepared with increasing amount of polymer while the amount of plasmid 
was the same for each.............................................................................. 67 
Table 5.4 : Illustration of average size, pDI and charge values for p(CBA-ABOL) 
pplxes with different polymer/pDNA mass ratios .................................. 68 
Table 5.5 : Illustration of average size, pDI and charge values for PEGylated 
p(CBA-ABOL) polyplexes with different polymer/pDNA mass ratios . 75  
Table 5.6 : Illustration of the amount of HA and pDNA used to apply the coating in 
appropriate HA/pDNA molar ratio ......................................................... 81  
Table 5.7 : The amounts of p(CBA-HIS) polymer and pDNA which was used to 
obtain desired polymer/pDNA (w/w) ratios. The polyplexes were 
prepared with increasing amount of polymer while the amount of plasmid 
was constant. ........................................................................................... 88 
Table 5.8 : Illustration of average size, pDI and charge values for p(CBA-HIS) 
polyplexes with different polymer/pDNA mass ratios ............................ 88 
 
 
  
xviii 
 
xix 
 
LIST OF FIGURES 
Page 
Figure 2.1 : Comparison of sizes of precellular organisms with an average cell in 
human body.  ............................................................................................. 3 
Figure 2.2 : A cross section from cell membrane (Bolsover, 2004)  .......................... 4 
Figure 2.3 : A general molecular formula of HSPGs where R= SO3
-
 (Gallagher et al, 
1986).......................................................................................................... 5 
Figure 2.4 : a. Categorisation of different endocytotic pathways, adapted from 
(Mayor and Pagano, 2007). b. Multiple routes of endocytosis into 
mamallian cells (Conner and Schmid, 2003). ........................................... 6 
Figure 2.5 : The mechanism of endocytosis.  ............................................................. 7 
Figure 2.6 : Cytosolic transport and nuclear import of the cargo, adapted from 
(Wong et al, 2007). .................................................................................... 8 
Figure 2.7 : The structure of cell nucleus [Url-1]. ...................................................... 9 
Figure 2.8 : Illustration of gene expression process [Url-2] ..................................... 10 
Figure 3.1 : a. Number of approved gene therapy clinical trials worldwide 1989-            
2011, b. Clinical phases of  approved gene therapy trials, adapted from 
[Url-3]...................................................................................................... 14 
Figure 3.2 : Intracellular barriers for gene delivery, adapted from (De Smedt et al, 
2005)........................................................................................................ 15 
Figure 3.3 : Schematic illustration of proton sponge hypothesis .............................. 19 
Figure 3.4 : Chemical structure of cationic lipid (A) DOTMA, (B) DOTAP and (C)   
an illustration of liposome, adapted from (Remaut et al, 2007). ............. 24 
Figure 3.5 : Chemical structures of selected polymers , adapted from (Wong et al, 
2007)........................................................................................................ 26 
Figure 4.1 :  Chemical structures of  a. DMAEMA monomer, b. pDMAEMA 
polymer.................................................................................................... 30 
Figure 4.2 : Illustration of radicalic polymerization reaction mechanism ................ 31 
Figure 4.3 : Illustration of Michael type polyaddition of a primary amine to bisacryl 
amide monomer, adapted from (Lin et al, 2007a) ................................... 35 
Figure 4.4 : Illustration of Michael type addition polymerization of a. p(CBA-
ABOL), b. p(CBA-HIS), adapted from(Coue and Engbersen, 2011) ..... 35 
Figure 4.5 : Illustration of Michael type addition polymerization of a p(CBA-
ABOL/DMEDA/PEG) copolymer, adapted from (Vader et al, 2012) .... 36 
Figure 4.6 : Schematic representation of pGL4.13 plasmid. The plasmid encodes for 
luc2 gene under the control of SV40 promoter. Amp
r
: ampicilline 
resistance marker [Url-4] ........................................................................ 39  
Figure 4.7 : Schematic representation of gWiz™-GFP plasmid. kanr: kanamycin 
resistance [Url-5] ..................................................................................... 40 
Figure 4.8 : Schematic illustration of zeta potential [Url-6] ..................................... 42  
Figure 4.9 : Main components and optical configurations of a Nano Ζeta-sizer 
instrument for DLS measurements [Url-7] ............................................. 44  
xx 
 
Figure 4.10 : Formation of polymer/DNA nanocomplex (polyplex) by self-assembly,  
adapted from (Coue and Engbersen, 2011) ............................................. 45  
Figure 4.11 : The scattering of laser in flow cytometer [Url-8] ................................ 50  
Figure 4.12 : Reduction of MTT reagent to formazan .............................................. 52 
Figure 5.1 : Illustration of 
1
H-NMR spectrum of DMAEMA monomer .................. 54 
Figure 5.2 : The 
1
H-NMR spectrum relative to TMS (CDCl3, 300 MHz and 
expressed in ppm) of pDMAEMA .......................................................... 55 
Figure 5.3 : 
1
H-NMR spectrum relative to D2O (D2O, 300 MHz and expressed in 
ppm) of p(CBA-ABOL) .......................................................................... 56 
Figure 5.4 : The 
1
H-NMR spectrum relative to D2O (D2O, 300 MHz and expressed 
in ppm) of p(CBA-HIS) .......................................................................... 56 
Figure 5.5 : Illustration of the Mw distribution of p(CBA-ABOL) obtained by gel 
permeation chromatography .................................................................... 57 
Figure 5.6 : Illustration of the Mw distribution of p(CBA-HIS) obtained by gel 
permeation chromatography   .................................................................. 57  
Figure 5.7 : Illustration of a. particle size and polydispersity, b. Ζ-potential of 
polyplexes formed by pDMAEMA with different Mw and mass ratios . 60 
Figure 5.8 : Agarose gel electrophoresis of pDMAEMA polyplexes Mw 50 kDa and 
600 kDa with different mass ratios. The lanes with the polyplexes contain 
20 µL of sample (corresponding to 200 ng of pDNA per well). As a 
negative control, 20 µL of heparin (7 μg/μL) was added to last 4 samples 
to simulate pDNA displacement .............................................................. 61 
Figure 5.9 : Comparison of cellular internalization of p(DMAEMA) polyplexes with 
different Mw and mass ratios. ................................................................. 62 
Figure 5.10 : Comparison of transfection efficiency of pDMAEMA polyplexes with 
different Mw and mass ratios and LF as a positive control ..................... 63 
Figure 5.11 : Cell viability results of pDMAEMA polyplexes with different Mw and 
polymer ratios .......................................................................................... 64 
Figure 5.12 : Illustration of  a. particle size and polydispersity, b. ζ-potential of 
p(CBA-ABOL) polyplexes with different mass ratios. ........................... 68 
Figure 5.13 : Agarose gel electrophoresis of p(CBA-ABOL) pplxes with different 
mass ratios. Each sample was colored with 5 µL loading buffer. The 
polyplex samples contain 0.2 µg of pDNA. As a negative control, 10 µL 
of Heparin (7 μg/μL) was added to last sample ...................................... 69 
Figure 5.14 : Comparison of cellular internalization of p(CBA-ABOL) polyplexes 
with different mass ratios ........................................................................ 70 
Figure 5.15 : Comparison of transfection efficiencies of p(CBA-ABOL) polyplexes 
with various mass ratios compared to LF. ............................................... 71 
Figure 5.16 : Cell viability results of p(CBA-ABOL)/pDNA polyplexes with 
different mass ratios ................................................................................ 72 
Figure 5.17 : Illustration of  the effect of PEGylation on a. particle size and 
polydispersity, b. ζ-potential ................................................................... 75 
Figure 5.18 : Agarose gel electrophoresis for p(CBA-ABOL/DMEDA/PEG) 
complexes. The lanes with the polyplexes contain 20 µL of sample 
(corresponding to 200 ng of pDNA per well). As a negative control, 5 µL 
of Heparin (7 μg/μL) was added to last 3 samples to simulate pDNA 
displacement. ........................................................................................... 77 
Figure 5.19 : The effect of  PEGylation on cellular internalization of p(CBA-ABOL) 
polyplexes with different mass ratios in ARPE-19 cells. ........................ 78 
xxi 
 
Figure 5.20 : Comparison of the effect of PEGylation on transfection efficiency of 
p(CBA-ABOL) polyplexes with various mass ratios in ARPE-19 cells.78 
Figure 5.21 : Illustration of the effect of HA-coating on a. particle size and 
polydispersity, b. ζ-potential of p(CBA-ABOL) polyplexes with different 
HA/pDNA molar ratios ........................................................................... 81 
Figure 5.22 : Agarose gel electrophoresis of HA-coated p(CBA-ABOL) polyplexes 
with different HA/pDNA molar ratios. The lanes with the polyplexes 
contain 20 µL of sample (corresponding to 200 ng of pDNA per well). 
As a negative control, 5 µL of Heparin (7 μg/μL) was added to last 4 
samples to simulate pDNA displacement................................................ 83 
Figure 5.23 : The effect of HA-coating on cellular internalization of p(CBA-ABOL) 
polyplexes with different HA/pDNA molar ratios in ARPE-19 cells ..... 84 
Figure 5.24 : Comparison of transfection efficiencies of different gene carriers HA-
coated p(CBA-ABOL) with different HA/pDNA molar ratios,  non-
coated p(CBA-ABOL) and LF complexes. ............................................. 84 
Figure 5.25 : Effect of HA-coating on the viability of ARPE-19 cells ..................... 85 
Figure 5.26 : Illustration of  a. particle size and polydispersity, b. ζ-potential of 
pDMAEMA polyplexes with different Mw and mass ratios .................. 89 
Figure 5.27 : Agarose gel electrophoresis of p(CBA-HIS) polyplexes with different 
mass ratios. The lanes with polyplexes contain 20 µL of sample 
(corresponding to 200 ng of pDNA per well). As a negative control, 3 µL 
of Heparin (7 μg/μL) was added to last 5 samples to simulate pDNA 
displacement. 48/1 p(CBA-ABOL) polyplexes were applied as a 
comparative reference. ............................................................................ 90 
Figure 5.28 : Comparison of internalization of different gene carriers p(CBA-HIS) 
with different mass ratios, p(CBA-ABOL) and LF in ARPE-19 cells.... 91 
Figure 5.29 : Comparison of transfection efficiencies of different gene carriers 
p(CBA-HIS) with different mass ratios, p(CBA-ABOL) and LF in 
ARPE-19 cells........................................................................................ 91 
Figure 5.30 : Cell viability results of p(CBA-HIS)/pDNA pplexes with different  
mass ratios ............................................................................................... 92 
Figure A.1 : Preliminary study for HA-coating  ..................................................... 111 
  
 
 
 
 
 
 
 
xxii 
 
xxiii 
 
EVALUATION OF CATIONIC POLYMER VECTORS FOR NON-VIRAL 
GENE DELIVERY 
SUMMARY 
Gene therapy has been a promising way to treat human genetic disorders. The major 
goal of gene therapy is to repair the genetic cause underlying the disorder by 
transferring the therapeutic nucleic acid with a safe and efficient carrier. For this 
purpose, two main classes of vectors are explained: viral and non-viral vectors. Even 
though, viral vectors are the most efficient carriers known, they have restrictions 
about their safety and production process. Cationic polymers have been the mostly 
investigated non-viral vector systems as a safe and easy-to-produce alternative to 
viral carriers. Moreover, numerous research have been done to increase their 
transfection efficiency. 
In this thesis study, two different types of cationic polymers were synthesized and 
investigated for their non-viral gene carrier potentials. One of them is a cationic, non-
biodegradable poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA). The 
second type of carriers is cationic and biodegradable linear, disulfide linkage 
containing poly(amidoamine)s (SS-PAAs) that include four different polymers with 
different side groups and coating strategies. The SS-PAA family consists of p(CBA-
ABOL), p(CBA-ABOL/DMEDA/PEG) with PEGylation strategy, p(CBA-ABOL) 
with HA-coating and lastly, p(CBA-HIS).  
The main objectives of this study were first of all, physicochemical characterization 
of the polymer/pDNA complexes with different polymer Mw and polymer/pDNA 
ratio in terms of size, polydispersity and surface charge which were measured by 
DLS. Secondly, the pDNA complexation ability of polyplexes was investigated by 
performing agarose gel electrophoresis. Thirdly, in vitro biological evaluation of 
polymers on ARPE-19 cells were performed. For this purpose, uptake and 
transfection efficiencies of the polymers and the effect of different polymer Mw’s 
and different polymer/pDNA ratios on uptake and transfection efficiency of 
polyplexes were evaluated by Flow Cytometry. Finally, the effect of polyplexes on 
the viability of ARPE-19 cells was analyzed with MTT Assay.     
While evaluating the pDMAEMA complexes, they showed the ability to form stable 
complexes in HEPES buffer and were able to efficiently complex pDNA. 
Nevertheless, the cationic nanoparticles formed with these polymers only exhibited 
signs of transfection in concentrations already toxic for the cells. This is why a new 
family of biodegradable polymers- the disulfide-containing PAAs, were investigated. 
p(CBA-ABOL) particles were also able to form stable polyplexes with efficiently 
complexed pDNA and also showed very high transfection efficiency, without 
significant effect on cell viability. Unfortunately, these nanoparticles were not stable 
in mimicked physiological conditions, which is why the same polymer was 
investigated with a PEG-chain as a universal coating strategy. Even though these 
particles were stable under physiological conditions, their uptake was drastically 
xxiv 
 
hindered. A different coating strategy with hyaluronic acid showed promising 
preliminary results, but the same results could not be observed with the research 
grade purity low Mw HA. Subsequently, another member of SS-PAA family with a 
different side chain and buffering capacity was evaluated. p(CBA-HIS) polymer was 
able to condense the pDNA in HEPES buffer and transfected the cells with almost no 
cytotoxic effect. However, the colloidal stability of p(CBA-HIS) polyplexes in 
physiological conditions should be further increased. 
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KATYONİK POLİMERLERİN GEN TAŞIYICI SİSTEMLERİ OLARAK 
DEĞERLENDİRİLMESİ 
ÖZET 
Gen tedavisi, genetik kaynaklı birçok hastalığa çözüm sunma potansiyeli açısından 
son yıllarda oldukça rağbet gören bir çalışma alanı olmuştur. Gen tedavisinin ana 
amacı hastalıkların ortaya çıkardığı semptomları iyileştirmeye çalışmak yerine, 
hastalığa sebep olan genetik bozuklukları ortadan kaldırmaktır. Bu tedavide, tedavi 
edici özelliği olan genler, en güvenli ve verimli bir taşıyıcı ile hedef dokuya ya da 
hücreye transfer edilmektedir. Bu amaçla kullanılan taşıyıcılar viral ve viral olmayan 
taşıyıcılar olmak üzere ikiye ayrılır. Viral taşıyıcılar, hedefe ulaşma verimliliği 
açısından bilinen en verimli taşıyıcılar olmakla birlikte güvenilirlik ve üretim 
aşamaları açısından uygulamaları çok kısıtlıdır. Bu sebeple, güvenli ve üretimi kolay 
alternatif bir metod olarak katyonik polimerler araştırılmaktadır. Literatürde, 
katyonik polimerlerin transfeksiyon verimliliklerini artırmak için yapılmış pek çok 
çalışmaya ulaşılabilir. 
Bu tez çalışmasında, gen tedavisi potensiyelleri açısından iki farklı polimer türü 
sentezlendi ve çeşitli özellikleri bakımından incelendi. Bu polimerlerin ilki, katyonik 
fakat biyobozunur olmayan poli(2-(dimetilamino)etil metakrilat) (pDMAEMA) 
polimeridir. İkinci tür taşıyıcı sistem ise katyonik ve biyobozunur disülfür bağı 
içeren, lineer poli(amidoamin) (SS-PAA) polimer türevleridir. SS-PAA ailesine ait 
farklı yan grup ve kaplama stratejileri ile sentezlenen 4 farklı polimer bu çalışmada 
incelendi. Bunlar poli-(N,N’-sistamin bisakrilamit-4-amino bütanol) p(CBA-ABOL), 
PEG’leme stratejisi ile geliştirilen p(CBA-ABOL/DMEDA/PEG),  hiyaluronik asit 
(HA) kaplanmış p(CBA-ABOL) ve son olarak da poli-(N,N’-sistamin bisakrilamit-
histamin) (p(CBA-HIS))’dir. Bu çalışmanın ilk aşaması olarak farklı molekül 
ağırlıklı ve farklı polimer oranlarına sahip polimer/pDNA (plazmit DNA) 
kompleksleri (polipleks) fizikokimyasal özellikleri açısından incelendi.  
Bu amaçla boyut, polidispersite ve yüzey yükü ölçümleri DLS cihazı ile yapıldı. 
İkinci olarak poliplekslerin pDNA’yı kaplayarak kararlı kompleksler oluşturma 
etkinlikleri agaroz jel elektroforez ile belirlendi. Bu karakterizasyonları takiben, 
polimer/pDNA komplekslerinin ARPE-19 hücreleri ile in vitro biyolojik 
değerlendirmeleri amaçlandı. Farklı molekül ağırlığına (MA) ve farklı polimer 
oranlarına sahip polipleksler hazırlanarak hücrelere transfer edildi ve hücre içine 
alınma ve genetik materyali hedefe ulaştırma verimlilikleri Hücre Sitometresi (Flow 
Cytometry) cihazı ile ölçüldü. Son olarak, poliplekslerin hücreler üzerindeki 
sitotoksik etkisi MTT Testi ile analiz edildi. 
pDMAEMA polimeri ile oluşturulan 2 farklı MA ve farklı polimer oranına sahip 
poliplekslerin HEPES tamponu ortamında yapılan boyut ve yük tayini sonuçlarına 
göre bu ortamda pDNA ile kararlı komplekler yapabildiği görüldü. Yapılan 
ölçümlerin fizyolojik ortama uygunluğunun denenmesi için aynı seri ölçümler bir de 
serum içermeyen transfeksiyon ortamı olan OptiMEM ortamında gerçekleştirildi. 
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OptiMEM ortamında kompleks kararlılığının azaldığı ve agregasyon oluşumu 
gözlendi. Bu ölçümleri takiben pDMAEMA polimerinin pDNA’yı kondanse 
edebilme özelliğinin analizi için pDMAEMA polipleksleri agaroz jel elektroforeze 
uygulandı. Her iki MA ve polimer oranındaki kompleksler pDNA kaplamaya 
muktedirdi. Polimer MA ve oranının polipleks kararlılığına bariz bir etkisinin 
olmadığı gözlendi fakat yüksek polimer oranına sahip kompleksler daha küçük 
parçacık boyutu gösterdiler. pDMAEMA poliplekslerinin in vitro biyolojik 
değerlendirilmesi sonuçlarına göre pDMAEMA/pDNA komplekslerinin hücre içine 
alınma verimlilikleri oldukça tatmin ediciydi. Fakat hücre içine alınan poliplekslerin 
çekirdeğe ulaşma potansiyelleri oldukça düşük ve ancak hücreler için toksik olan 
polimer miktarlarında ilgi çekici sonuçlar verdi. 
SS-PAA polimerleri içerdikleri tekrarlanan sülfür köprüleri sayesinde biyobozunur 
polimerler olduklarından gen salımı konusunda iyi bir potansiyele sahiptirler. Bu 
ailenin ilk üyesi olarak p(CBA-ABOL) polimeri gen taşıyıcısı olarak değerlendirildi. 
pDMAEMA polipleksleri için yapılan tüm işlemler p(CBA-ABOL)/pDNA 
komplekleri için de denendi. Farklı polimer oranlarıyla oluşturulan p(CBA-ABOL) 
komplekslerinin yüzey yükü ve boyut tayini HEPES ve OptiMEM ortamlarında 
gerçekleştirildi. HEPES ortamında artan polimer miktarının daha kararlı kompleksler 
oluşturmasına karşılık, aynı komplekslerde OptiMEM ortamında agregasyon 
gözlendi. Agaroz jel elektroforez sonuçlarına göre yüksek polimer oranları 48/1 ve 
96/1 ile oluşturulan kompleksler pDNA’yı kaplama açısından daha elverişli idiler. 
p(CBA-ABOL) poliplekslerinin in vitro biyolojik değerlendirilmelerinin sonucunda 
ise p(CBA-ABOL) poliplekslerinin genetik materyalin hücre içine alınması ve 
ardından çekirdeğe ulaştırılması açısından pDMAEMA komplekslerine göre daha 
verimli olduğu ayrıca ARPE-19 hücreleri için yalnızca ihmal edilebilir düzeyde bir 
toksisiteye sebep olduğu görüldü. 
p(CBA-ABOL) komplekslerinin fizyolojik ortamdaki agregasyonunu engellemek 
amacıyla evrensel bir strateji olan PEG’leme stratejisi kullanıldı. PEG’lenen p(CBA-
ABOL) polimeri ile oluşturulan kompleksler de daha önceki ölçümlere tabi tutuldu. 
PEG’leme sonucunda komplekslerin OptiMEM ortamındaki kolloidal kararlılığında 
artış gözlenirken in vitro biyolojik değerlendirme açısından PEG’lenen p(CBA-
ABOL) polimeri ile yapılan ölçümler istenilen verimi göstermedi. Hücre içine alınma 
verimliliği açısından PEG’lenmiş komplekslerin yok denecek kadar az bir 
potansiyellerinin olduğu gözlendi. Kompleksler hücre içine alınmadığından 
sitotoksisite analizine gerek duyulmadı. 
p(CBA-ABOL) komplekslerinin hücre içine alınma kapasitelerinin artırılması için 
kompleksler bir hücre zarı proteini olan HA ile elektrostatik olarak farklı HA/pDNA 
oranlarında kaplanarak önceki polimerler ile aynı şekilde fizikokimyasal ve biyolojik 
değerlendirmelere tabi tutuldu. Komplekslerin dış kabuğu anyonik HA ile 
kaplandığından yüzey yükünün pozitiften negatife döndüğü gözlendi. Parçacık 
boyutu ve kolloidal stabilite açısından ise kaplanmamış p(CBA-ABOL) 
komplekslerine göre OptiMEM ortamında daha kararlı kompleksler elde edildi. 
Biyolojik değerlendirme sonuçlarında, poliplekslerin hücre içine alımında HA 
kaplama ile elde edilmek istenen artış gözlenmedi. 
En son taşıyıcı sistem olarak SS-PAA polimerlerinin bir türevi olan p(CBA-HIS) 
polimeri ile oluşturulan kompleksler gen taşıma kapasiteleri açısından 
değerlendirildi. 
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HIS yan grubu, ABOL yan grubuna göre daha asidik olduğundan komplekslerin 
hücre içine endozomlar vasıtasıyla alınmasını takiben endozomlardan çıkışı 
artıracağı ve buna bağlı olarak çekirdeğe ulaşan kompleks miktarının artacağı 
amaçlandı. p(CBA-HIS) kompleksleri kolloidal karalılık ve pDNA kondenzasyonu 
açısından p(CBA-ABOL) kompleksleri ile benzer özellikler gösterdiler. Aynı şekilde 
in vitro ölçümler sonucuda p(CBA-HIS) komplekslerinin hücre içine alınma 
kapasitelerinin daha yüksek olmasına rağmen genetik materyalin çekirdeğe ulaşma 
verimliliği açısından amaçlanan artış gözlenmedi. 
Sonuç olarak pDMAEMA polimer/pDNA komplekslerinin artan molekül ağırlıkları 
ve polimer miktarları hücreler üzerinde toksik etki yaparken, SS-PAA polimerlerinin 
transfeksiyon açısından iyi bir potansiyellerinin olduğu tespit edildi. Bu gruptan son 
olarak incelenen p(CBA-HIS) poliplekslerinin HEPES tamponu ortamında pDNA’yı 
kondanse etmesi ve transfekte ettiği hücreler üzerinde sitotoksik aktivite 
göstermemesine rağmen agregasyon oluşumu tamamen engellenemedi. Bu nedenle 
bu poliplekslerin fizyolojik şartlardaki davranışlarının daha ileri araştırmalarla 
incelenmesi gerekmektedir. 
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1.  INTRODUCTION 
Gene therapy has been a promising way to treat human genetic disorders during the 
last two decades. The major goal of gene therapy is to repair the genetic cause 
underlying the disorder by transferring therapeutic nucleic acids with a safe and 
efficient carrier to the target cells. For this purpose, two main classes of vectors are 
explained: viral and non-viral vectors. Even though viral vectors are the most 
efficient carriers known, they have restrictions about their safety and production 
process and they are reported to have immune response after repeated 
administrations (Thomas et al, 2003). Synthetic non-viral vectors such as cationic 
polymers have been the mostly investigated gene delivery systems as a safer and 
easy-to-produce alternative to viral carriers (De Smedt et al, 2000). 
The most recently studied examples of cationic polymer vectors include 
polyethylenimine (PEI), poly(L-lysine) (PLL), poly(amidoamine) (PAA) and poly(2-
(dimethylamino)ethyl methacrylate) (pDMAEMA). In this project pDMAEMA, and 
a new class of PAAs with repetitive disulfide linkages in the polymer backbone (SS-
PAAs) were chosen to be synthesized and evaluated as potential gene delivery 
systems.  
pDMAEMA has attracted the attentions by being readily synthesized via radicalic 
polymerization and having relatively high transfection efficiency (van de Wetering et 
al, 1997). Moreover, PAAs are widely investigated since they are highly 
biocompatible and biodegradable (Ferruti et al, 2002). SS-PAAs have been 
previously described as a new bioreducible class of PAAs. They can be synthesized 
by Michael-type addition polymerization of amine compounds to disulfide 
containing bisacrylamides (Lin et al, 2007a). 
1.1 Purpose of The Thesis 
The main purpose of the study described in this thesis is first of all, synthesis of 
cationic polymer vectors for gene delivery applications. Secondly, physicochemical 
characterization of the polymer/pDNA complexes with different polymer Mw and 
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polymer/pDNA ratio was done in terms of size, polydispersity and surface charge. 
Thirdly, the ability of the polymers to condense and retain the plasmid DNA in an 
electrostatic complex was investigated. Subsequently, in vitro biological evaluations 
of polymers were aimed. For this purpose, the effect of different polymer Mw’s and 
different polymer/pDNA ratios on uptake and transfection efficiencies was 
evaluated. Finally, the influence of polyplexes on the viability of cells was analyzed. 
1.2 Outline of The Thesis 
In the first following chapter, in order to give a background about general cell 
biology, the main components of an eukaryotic cell that are related to the journey of 
a gene carrier system are briefly explained. 
In the “Gene Therapy” chapter, because the understanding of the efficiency of the 
polymers to transfer the therapeutic genetic material to its target depends on 
understanding the various gene delivery barriers that a carrier system has to 
overcome, the major barriers for gene delivery are explained in relation to the 
biological chapter. Subsequently, the most leading gene delivery methods including 
physical, viral and synthetic methods to overcome these barriers are introduced 
according to literature. 
The other two chapters describe the materials and methods used in this study and the 
results obtained, respectively. Finally, the concluding remarks about the results of 
this project can be found in conclusion. 
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2.  BASICS OF CELL BIOLOGY 
2.1 The Cell 
The cell is the smallest living unit of an organism. The term “cell” was defined for 
the first time by Robert Hooke (1635-1702), an English physicist (Mazzarello, 1999). 
Following the developments and technical improvements in microscopy science in 
late 18
th
 century, scientists became interested in visualizing the living organisms. 
Then it was stated by a German physician and physiologist Theodore Schwann 
(1810-1882) that animal tissues are comprised of cells and each cell has a nucleus  
(Hajdu, 2002). Three centuries after the first discovery of the cell, today it is 
estimated that there are ±10 trillion cells in a human body. Still, not all the cells have 
the same function in the body and are specialized to carry out different functions, 
such as epithelium, muscle and neuron cells. In general, cells have a size ranging 
from 10 µm to 50 µm, yet depending on its function this can vary (See Figure 2.1). 
 
Figure 2.1 : Comparison of sizes of precellular organisms with an average cell 
in human body. 
2.2 Cell (Plasma) Membrane  
The cell membrane (or plasma membrane) is the protective boundary of a cell with a 
thickness of 3 nm (Chen and Moy, 2000). The semi-permeability of the cell 
membrane regulates what is being taken into cell and what is being given out of the 
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cell. Besides, this selectively permeable membrane controls the electrical and 
chemical signals between cells. Lipids form half of the mass of cell membrane, while 
the other half is made up of proteins, cholesterol and sugars (carbohydrates), (See 
Figure 2.2). 
The lipid bilayer of the membrane is built up through self assembly of phospholipid 
molecules. These lipids contain a hydrophilic phosphate head, which is soluble in 
water, and a hydrophobic fatty acid tail, which is soluble in lipid. Because 
hydrophobic tails are repelled by the water molecules of intracellular and 
extracellular fluids, they are located in the inner part of the bilayer membrane while 
the hydrophilic heads are in contact with intracellular and extracellular fluids 
(Bolsover, 2004). 
 
Figure 2.2 : A cross section from cell membrane (Bolsover, 2004). 
The proteins in the cell membrane maintain the chemistry of the cell and the transfer 
of the chemical messages into the cell. The highly hydrophobic environment of the 
lipid bilayer makes it easier for the fat soluble molecules such as oxygen, carbon 
dioxide and alcohols to enter the cell. On the other hand, specific proteins form pores 
on the membrane and this way, also water soluble molecules such as ions, glucose, 
amino acids and urea can diffuse into the cell (Edidin, 2003), (Poo and Cone, 1974).  
There are sugar chains which are called glycosaminoglycans (GAGs) attached via 
protein moeties to the outer surface of the membrane. These protein-carbohydrate 
complexes, called proteoglycans (PGs) play a crucial role in determining the charge 
characteristic of the cell membrane. The most abundant PG on the cell surface is the 
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polyanionic heparan sulphate proteoglycans (HSPGs), which makes the cell 
membrane negatively charged (Perrimon and Bernfield, 2000), (See Figure 2.3). 
Thus, any compound with negative electrical charge will be electrostaticaly repelled 
by the cell membrane, whereas positively charged particles will readily adhere to the 
cell surface. 
 
Figure 2.3 : A general molecular formula of HSPGs where R= SO3
-
 (Gallagher et al,      
1986). 
2.3 Cellular Entry of Extracellular Material 
2.3.1 Endocytosis and endosomes 
A cell internalizes the nutrients which are necessary to maintain its functions from 
the extracellular environment. Diffusion and active transport are the most common 
ways that small substances such as amino acids, sugars and certain ions use to pass 
through the cell membrane (Conner and Schmid, 2003). Diffusion is the simple and 
passive movement of a particle (atom, ion or molecule) according to concentration 
gradient. Particles are transported from a region in which they have higher 
concentration to a region of lower concentration. Active transport is an energy-
demanding process that can occur when a particle needs to be passed against the 
concentration gradient, i.e., from lower concentration to higher concentration. It is 
assisted by special protein carriers.  
However, very large molecules cannot enter through cell membrane neither via 
diffusion nor active transport. They use a specialized function of the cell membrane 
which is called endocytosis to be taken up by the cell. There are several routes 
described for endocytosis, but the main mechanism remains the same. In general, 
endocytotic pathways can be divided into two major categories: phagocytosis, which 
is the uptake of large particles, and pinocytosis, which entails the uptake of fluid and 
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solutes (See Figure 2.4). Phagocytosis can be seen only in specialized mammalian 
cells while pinocytosis occurs in all cell types (Conner and Schmid, 2003). 
Moreover, pinocytosis has 4 subcategories: macropinocytosis (Apodaca, 2001), 
clathrin-dependent endocytosis, caveolae-mediated endocytosis and clathrin- and 
caveolae- independent endocytosis (Gong et al, 2008) (Nichols and Lippincott-
Schwartz, 2001). These routes differ from each other with regard to the size and 
formation mechanism of the vesicle and the nature of the cargo that is being taken up 
(Conner and Schmid, 2003). 
 
Figure 2.4 : a. Categorization of different endocytotic pathways, adapted  from 
(Mayor and Pagano, 2007). b. Multiple routes of endocytosis into 
mammalian cells (Conner and Schmid, 2003). 
During endocytosis, the plasma membrane invaginates and engulfs some of the 
extracellular fluid containing the foreign material (cargo). When two portions of the 
plasma membrane reencounter each other, a part of the membrane pinches off and 
forms an internal membrane-bounded vesicle named endosome (See Figure 2.5). 
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Figure 2.5 : The mechanism of endocytosis. 
The pH of the endosomal compartment is around 6 when the vesicle is near the cell 
membrane. As the endosomal vesicles mature and get closer to a lysosomal state and 
then to the nucleus it becomes more acidified (pH ~5) by the  proton pumps (H
+
-
ATPase) of the endosome (Wong et al, 2007), (Luby-Phelps, 2000). The endocytotic 
transport pathway is followed by lysosomal digestion of the cargo material. 
2.3.2 Lysosome 
Lysosomes are the organelles containing hydrolitic enzymes which are specialized in 
the digestion of  intra- and extracellular compounds (Ciftci and Levy, 2001). The 
enzymes are optimally active at pH 5 to digest damaged cellular structures, 
exogeneous materials -the compounds that are not wanted inside the cell- and the 
food particles that have been taken into the cell (Rybak and Murphy, 1998). 
Immediately after the cargo is taken up by endosomes, one or more lysosomes attach 
to the endosome and the vesicle becomes acidified by proton pumps. The vesicular 
hydrolytic enzymes of the lysosomes start to digest proteins, carbohydrates and lipids 
to their building blocks amino acids, glucose and phosphates respectively. These 
small digestion products can be delivered out of the vesicle to the cytosol. The 
indigestible substances (residual body) are excreted through the cell membrane by a 
process called exocytosis –the opposite mechanism of endocytosis. 
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2.4 Intracellular Environment 
2.4.1 Cytoplasm and cytosol 
Cytoplasm - the intracellular matrix - contains high volume of water while holding 
the organelles inside. The watery-liquid part of the cytoplasm without any organelles 
is defined as cytosol. It is a mixture of substances dissolved in water such as salts, 
nutrients and some macromolecules. Additionally, cytosol contains nucleolytic 
enzymes (nucleases), which are ready to degrade nucleic acids, distributed over the 
cytoskeleton (Lechardeur and Lukacs, 2006) and intracellular reduction agents that 
can cleave bioreducible foreign materials (Saito et al, 2003). The pH of intracellular 
fluid ranges between 6.8 - 7.4 depending on the cell type and biological mechanism 
and viscosity of the cytosol is nearly the same as pure water (Bright et al, 1987). The 
major function of the cytosol is to help the transport of the metabolites and 
compounds, through cytoskeleton, from their place of production to the place that 
they will be used. 
2.4.2 Cytoskeleton 
The cytoskeleton is a dynamic structure, maintaining the cell shape, mechanical 
resistance of the cell and cytoplasmic transport of organelles and large molecules 
inside the cell (Luby-Phelps, 2000). It has a network of proteins which form the 
microtubules (MTs), actin filaments (microfilaments) (MFs) and integrated filaments 
(IFs), (See Figure 2.6). 
 
Figure 2.6 : Cytosolic transport and nuclear import of the cargo, adapted from 
(Wong et al, 2007). 
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The cytoplasmic MTs are responsible for intracellular trafficking of vesicles, proteins 
and organelles (Fuchs and Yang, 1999). The actin MFs gives the cell polarity and 
contractility for migratory processes (Apodaca, 2001). Finally, the IFs provides the 
need for mechanical integrators of cytoplasm (Fuchs and Yang, 1999). 
2.5 Cell Nucleus 
2.5.1 Function 
The cell nucleus is the control center of the eukaryotic cells. It is the largest organelle 
in animals cells and can fill up to 10 % of the cell space with an average diameter of 
6 μm (Lodish, 2004). Nuclear envelope, nuclear pores, nucleolus and genetic 
material (chromosomes and chromatins) form the main structure of a cell nucleus 
(See Figure 2.7). The nucleus coordinates essential cellular activities including 
growth, protein synthesis and cell division. The genetic material in the nucleus is 
very well protected by the nuclear envelope - the bilayer membrane of the nucleus. 
 
Figure 2.7 : The structure of cell nucleus [Url-1]. 
2.5.2 Nuclear envelope and pores 
The nuclear envelope encloses the nucleus separating the nucleoplasm and genetic 
material from the cytoplasm by a double membrane (Gorlich and Mattaj, 1996). The 
inner membrane which is called nuclear lamina is made from proteins and gives extra 
rigidity to nucleus. The inner and outer membranes are penetrated with thousands of 
nuclear pores.  
The transport of macromolecules, such as proteins, from cytoplasm to the interiors of 
nucleus, is controlled by highly selective membrane proteins through the formation 
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of an aqueous channel (Laskey et al, 1996). These proteins are termed as nuclear 
pore complexes (NPCs). The NPCs recognize the macromolecules which are 
forwarded to the nucleus and provide the energy for their translocation into nucleus. 
The recognition process is guided by nuclear localization signals (NLSs) (Pouton, 
1998). NPCs allow passive diffusion of metal ions, small metabolites and molecules 
less than 40kDa in mass with diameters of 5 nm (Wente and Rout, 2010). 
Nevertheless, there are particles known with a diameter up to 26 nm that can pass the 
nuclear pores if a suitable NLS guides the particle (Dworetzky and Feldherr, 1988).  
Moreover, breakdown of the nuclear envelope during the cell division, gives a 
possibility for nuclear entry of some macromolecules like exogenous DNA (Wilke et 
al, 1996). 
2.6 Gene Expression 
Gene expression is the process of synthesis of a functional gene product by using the 
information from another gene (See Figure 2.8). 
 
Figure 2.8 : Illustration of gene expression process [Url-2]. 
2.6.1 Transcription 
Transcription is the first step of gene expression that takes place in the nucleus by 
means of enzymatic complexes that are produced by specific genes. In this step 
ribonucleic acid (RNA) copies of deoxyribonucleic acid (DNA) are produced. The 
three major classes of RNA are ribosomal RNA (rRNA), transfer RNA (tRNA), and 
messenger RNA (mRNA). All play crucial roles in protein synthesis. During 
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transcription, the double helix of DNA is opened, and one strand of DNA is used as a 
pattern for the production of an RNA molecule (Bolsover, 2004). 
2.6.2 Translation 
Genes encoding mRNAs are known as protein-coding genes. Translation follows the 
transcription process. In this step a single strand mRNA, which was transcribed from 
double stranded DNA in the nucleus, produces proteins (polypeptides) (Lodish, 
2004). 
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3.  GENE THERAPY 
Gene therapy is the treatment of human diseases with an underlying genetic cause by 
delivering therapeutic genetic material (transgene) into the diseased cells of the 
patient. It has been a promising way to treat genetic diseases over the last decades 
because it offers a solution to treat the causes of diseases rather than curing the 
symptoms (Mountain, 2000). When a gene has a mutation, it becomes unable to 
express the proteins that it encodes for or the mutation can cause the production of 
inactive or toxic proteins. In both cases, the vital cell functions are affected and 
eventually induce symptoms. Consequently, gene therapy can be used to treat 
diseases caused by a defect in a particular gene such as cystic fibrosis (CF) (Russ and 
Wagner, 2007), or  to treat acquired redoubtable diseases such as cancer and acquired 
immunodeficiency syndrome (AIDS) (Ledley, 1995). The efficiency of gene therapy 
depends on the delivery of DNA to target cells and long-term expression of the gene 
(Naik et al, 2009). 
3.1 A Brief History of Gene Therapy 
The first approved clinical trials of gene therapy took place in United States in 1990 
(Scollay, 2001). One of those two ex vivo trials was employed to cure an enzyme 
deficiency that causes severe combined immunodeficiency (SCID) and the other as 
an immunotherapy for melanoma (Blaese, 1995). Both of them relied on viral vectors 
for the transfection of the therapeutics into cells, but neither of them were successful 
applications. Then scientists had an encouraging result in 1995, with the treatment of 
a four year old girl – an SCID patient. Although the disease was not treated, it was 
under a better control after the treatment (Blaese, 1995).   Nearly a decade after the 
initial thoughts occurred about gene therapy, more than 175 clinical trials were done 
and 2000 patients were already treated (G. Ross et al, 1996). However, the first 
decade ended tragically with the death of a 18-year old patient who suffered from a 
hepatic metabolic disorder - ornithine transcarbamylase (OTC) deficiency (Edelstein 
et al, 2004). He was being treated with a viral vector but during the clinical safety 
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trial, he had an adverse patient reaction which affected his immune system and 
caused  fatality in 1999 (Thomas et al, 2003). 
Then the millennium brought the success together for gene therapy. In 2000, three 
children had been treated for SCID and the first actual healing with gene therapy was 
reported (Cavazzana-Calvo et al, 2000). Unfortunately the success lasted shortly, 
because three years after, two of these patients were diagnosed with leukemia 
(Thomas et al, 2003). 
After all the trials with failure, there were some lessons to be learned. Scollay (2001) 
suggested that scientists had to base their studies more on the development of safer 
and feasible technologies rather than unrealistic expectations. 
According to the survey of Journal of Gene Medicine Clinical Trial Database (See 
Figure 3.1), there have been 1786 approved clinical trials evidenced in worldwide 
since the year 1989. Although the idea of treating the causes of diseases is only three 
decades old and most of the clinical trials are still on phase I, with the acceleration 
and success gained, it is a candidate to revolutionize the treatment of genetic 
disorders. 
 
         Figure 3.1 : a. Number of approved gene therapy clinical trials worldwide 
1989-  2011, b. Clinical phases of approved gene therapy trials, 
adapted from [Url-3]. 
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3.2 Barriers for Gene Delivery 
In general, gene therapy involves the delivery of the transgene which is encoded to 
produce a specific protein, into the patient’s somatic cells. In order for the 
therapeutic nucleic acid to be effective, it should overcome both extracellular and 
intracellular barriers. Delivering the pDNA has additional hurdles than delivering 
mRNA, since the pDNA has to be tranfered into nucleus for mRNA transcription, 
whereas the translation of mRNA occurs in cytoplasm.  
These barriers for pDNA delivery can be summarized into following steps as in 
Figure 3.2: 
I. stability in the extracellular environment, 
II. cellular attachment and adhesion, 
III. cellular uptake,  
IV. endosomal escape,  
V. cellular translocation and 
VI. nuclear import. 
 
Figure 3.2 : Intracellular barriers for gene delivery, adapted from (De Smedt et al, 
2005). 
3.2.1 Stability in the extracellular environment 
Due to the phosphate groups present in the DNA backbone, it is negatively charged. 
Also, DNA is not a small molecule that can easily be delivered. It has a bulky 
structure which has to be condensed in order to ensure cellular internalization. 
Moreover, the plasmid should be protected against the existence of degradation 
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enzymes (nucleases) both in the extracellular and intracellular environment  
(Abdelhady et al, 2003) (Lechardeur et al, 1999). The stability of the therapeutics in 
the extracellular environment such as intravascular spaces is highly related to the 
chemical stability of DNA. The exogenous negatively charged materials such as 
GAGs and serum albumin cause instability of non-viral cationic carriers. The 
potential carrier which will answer the requirements mentioned above has to provide 
colloidal stability for carrier/DNA complexes. It is observed for the systems, which 
require high concentration of cationic lipid or polymer particles to deliver the 
therapeutic DNA molecule, that in the presence of excess positive charge complexes 
readily aggregate (Davis, 2002).  
There are different strategies which have been tried to avoid aggregation of the 
complex particles in heterogeneous extracellular milieu. One of them is the covalent 
attachment of biocompatible hydrophilic polymers such as polyethylene glycol 
(PEG) or polyhydroxypropyl methacrylate (pHPMA) to the cationic carrier, to 
provide a steric barrier against aggregation. Since PEG is the most favored polymer 
for this purpose, it has given the name to the strategy as PEGylation. Covalent 
coupling of PEG can be performed either before the polyplex formation 
(prePEGylation) (Kursa et al, 2003) or after the polyplex formation (postPEGylation) 
(Ogris et al, 1999). The effectiveness of PEGylation to form stable complexes both 
for cationic lipid and polymers has been proved (Hong et al, 1997) (Y. H. Choi et al, 
1998). In addition to increased solubility (Ogris et al, 2003) and stability, PEGylation 
also provides lower toxicity and extended circulation time in blood, which can be 
perceived as a heterogeneous extracellular compartment with high ionic strength 
(Wagner and Kloeckner, 2006).  
3.2.2 Cellular attachment and adhesion 
When the stability of the complexes is ensured, the first obstacle is the attachment to 
the cell membrane. There are two main factors affecting the cellular association of 
cationic lipid or polymer carriers. First of all, the colloidal stability of the complexes 
has a major impact on the cellular attachment of the complexes. It has been shown 
that particles which form aggregates can better manifest the cellular attachment in 
vitro (P. C. Ross and Hui, 1999). Nevertheless, from a pharmaceutical point of view 
these aggregation events are dangerous and undesirable. Secondly, the cellular 
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attachment and adhesion of cationic particles is thought to be mediated by the 
interactions with anionic cell surface HSPGs (Wiethoff and Middaugh, 2003). These 
PGs are involved in various cellular processes as well as cellular attachment and 
adhesion (Bernfield et al, 1999). The interruption of HSPG expression on the cell 
surface results in a decrease in the amount of cellular associated-DNA and posterior 
transgene expression in vitro (Mislick and Baldeschwieler, 1996). Furthermore, for 
cationic lipid or polymer based gene delivery systems it is clearly shown that, the 
presence of HSPGs increases the efficiency of gene delivery (Belting and Petersson, 
1999). 
3.2.3 Cellular uptake 
After successful attachment to the cell membrane, the second challenge for a gene 
delivery system is being taken up by the cell. Due to size restrictions, passive 
diffusion through the cell membrane is not possible for these systems. In general, 
cationic carrier systems enter the cell via endocytosis with non-specific electrostatic 
interaction between positively-charged lipoplexes or polyplexes and negatively-
charged cell membrane GAGs. As it is described in the section 2.3.1, endocytosis 
occurs mainly in 5 different pathways: phagocytosis, pinocytosis, clathrin-dependent, 
caveolae-mediated and clathrin- and caveolae independent endocytosis. Most of the 
lipid carrier systems are explained to be taken up via clathrin-dependent endocytosis  
(Pichon et al, 2010). The uptake mechanism of polyplexes is more diverse depending 
on the cell size and type, the charge and side group characteristics of the polymer 
(Midoux et al, 2008). 
In addition to the non-specific endocytotic entry to the cell, targeting is a strategy to 
obtain cell specific gene delivery and increase the uptake specificity for the 
internalization of the carrier system. Targeting the gene delivery system to a specific 
cell can be employed by using target specific receptors or ligands. This strategy gives 
the chance to design the delivery system containing the target-ligand according to the 
aimed cell type. Mainly, electrostatic, conjugative or covalent coupling are being 
used for ligand binding purposes. The most favored and successful targeting 
molecules are transferring (Schatzlein, 2003), galactose (Zanta et al, 1997) and the 
RGD (arginine-glycine-aspartate) peptide (Kunath et al, 2003). Additionally, cell-
penetrating peptides are being investigated as a strategy to enhance the cellular 
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uptake (Heitz et al, 2009). These are positively charged peptides which are derived 
from viral proteins and have a length of 5-40 amino acids. They can be conjugated to 
the cargo material either covalently or non-covalently and their uptake mechanism is 
clearly explained by El-Andaloussi et al. (2005). 
Moreover, as cellular internalization and uptake of polyplexes are mediated by cell 
surface GAGs, it has been shown that the use of high concentrations of exogenous 
GAGs for targeting purposes increased the uptake and transgene expression 
efficiency of complexes (Mounkes et al, 1998). One example of the GAGs is 
hyaluronic acid (HA) which is used as a shielding and coating material to increase 
specific cellular uptake. The uptake mechanism of HA-coated particles has been 
explained to be receptor-mediated endocytosis that is facilitated by CD-44 receptors 
(Knudson et al, 2002). HA and CD44-mediated uptake and targeting is specifically 
used in tumor targeting (K. Y. Choi et al, 2010). 
3.2.4 Endosomal escape 
Once the complexes are internalized by endosomal vesicles, the endosomal 
compartment becomes acidified by proton pumps (H
+
-ATPase) and the luminal pH 
drops. The therapeutic polymer-gene complexes undergo a pH drop from 7.4 on the 
cellular surface to 5.5 inside the endosomal lumen. As the vesicle matures from 
endosome to lysosome the pH gets even more acidic around pH 4.5-5.0, and the 
therapeutic DNA is faced with different types of nucleases in the lysosome. Hence, 
to avoid degradation of the therapeutic nucleic acids in the lysosomes and ensure 
high transfection in the diseased cell, it is essential for any gene delivery vector to be 
able to escape from the endosomes in time (Wiethoff and Middaugh, 2003).   
For cationic lipid based gene delivery systems, their escape from endosomes is 
thought to be mediated by lipid mixing (flip flop mechanism) between endosomal 
and cationic lipid membranes and subsequently destabilization of the membrane and 
release of DNA into cytoplasm (Xu and Szoka, 1996).  
In case of the cationic polymer vectors, there are two possible hypotheses involved in 
their endosomal escape mechanism. One of them supports that the direct electrostatic 
interaction between negatively charged endosomal membrane and cationic polymer 
causes membrane disruption. Such a mechanism has been suggested for poly(amido 
amine) (PAMAM) dendrimers and poly(lysine) vectors (Zhang and Smith, 2000). 
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The second and most common explanation for the endosomal escape mechanism of 
cationic polymers with ionizable amine groups is the proton sponge hypothesis 
(Boussif et al, 1995), even if it is debatable (Funhoff et al, 2004). This hypothesis 
came up with the poly(ethyleneimine) (PEI) polyplexes, since PEI has a high 
cationic-charge-density potential, due to the presence of multiple protonable amino 
groups. Besides, PEI is only 20% protonated at physiological pH and can have a 
buffering effect nearly at any pH (Boussif et al, 1995). During the maturation of the 
endosomal vesicle, as it pumps protons and becomes more acidic, PEI-like polymers 
can act like a proton sponge, accept the protons and effectively buffer the decreasing 
pH. On the other hand, these accumulated protons disturb the endosomal pH and 
endosomal ATPases tend to keep the pH constant in the endosomes (See Figure 3.3). 
They balance the H
+
 influx by the influx of counter Cl
- 
anions to maintain the 
electroneutrality. This huge increase of ionic concentration inside the endosomes 
causes osmotic swelling by the influx of water and results in the bursting of 
endosomal membrane, eventually releasing its content. 
   
Figure 3.3 : Schematic illustration of proton sponge hypothesis. 
3.2.5 Cellular translocation to the nucleus 
Polyplexes that enter to cytosol following the endolysosomal release, are 
immediately faced with a contentious environment. The nucleolytic degradation 
enzymes are ready to degrade unprotected DNA, and the actin and tubulin filaments 
from the cytoskeleton form a dense network which can act as a diffusional barrier. 
The diffusion coefficient of the naked DNA in the cytoplasm is found to be highly 
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dependent on the plasmid size. However, the cytoskeleton does not allow the 
diffusion of naked DNA greater than 85 nm, thus polyplexes (150-200 nm) can reach 
to the nucleus only through active transport, provided by molecular motor proteins 
which are attached to the MTs or MFs (Luby-Phelps, 2000), (Dauty and Verkman, 
2005). 
3.2.6 Nuclear import 
The translation of mRNA occurs in cytosol while pDNA transcription occurs in the 
nucleus. For this reason, pDNA therapy has to deal with one additional barrier during 
the entry to nucleus.  
There are three possible routes for a molecule to overcome the nuclear envelope and 
enter the nucleus. One of them suggests that as the nuclear membrane breaks down 
during cell division, the DNA molecule can diffuse into the nuclear environment of 
the dividing cell (Gorlich and Mattaj, 1996). Most of the gene delivery systems are 
thought to transport their genetic material by this way. Second way is the passive 
diffusion of the molecules less than 5 nm through nuclear membrane (Wente and 
Rout, 2010). However, this way is not applicable due to size restrictions of the DNA 
molecule. The third route depends on the ability of a macromolecule to interact with 
the nuclear transport system. Highly selective membrane proteins -the nuclear pore 
complexes (NPCs) - present on this transport system, recognize a macromolecule by 
the guidance of nuclear localization signals (NLSs) (Pouton, 1998). Particles less 
than 26 nm in diameter can be actively transported through NPCs. DNA molecules 
can be condensed by NLSs via electrostatic interactions or NLSs can be bound to the 
polymer vector for nuclear targeting. Zanta et al. have shown that a 10- to 1000-fold 
enhanced transfection can be achieved with NLS conjugated DNA compared to DNA 
without NLS (1999). 
Another important barrier to obtain an effective gene transfer for a non-viral vector 
system is the unpacking of the vector (Schaffer et al, 2000). A successful 
transcription and enhanced gene expression require safe and effective dissociation of 
the vector/DNA complex. As polymeric vectors are the subject of this thesis, gene 
unpackaging strategies for polymers will be discussed in the next section.                                           
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Overall, the successful transfer of nucleic acids to the nucleus and dissociation of 
DNA is followed by the transcription of the genes to mRNA and subsequently 
translation to the therapeutic protein in the cytosol. 
3.3 Methods for Gene Delivery 
The previously mentioned challenges for gene delivery, make the delivery of naked 
DNA inefficient and enforces to use a physical method or combine it with a vector. 
Many types of physical methods and vector systems have been developed for this 
purpose. 
3.3.1 Physical methods 
3.3.1.1 Gene gun 
This is a method based on applying physical force for the gene transfer.  For the 
delivery process, DNA-coated gold nanoparticles are accelerated by a high-pressure 
helium steam (Mhashilkar et al, 2001). This method is also called “needle-free 
injection” because the method allows gene delivery injection without the use of 
needles (Mountain, 2000). The created force can deliver the DNA directly into the 
cytoplasm and can be used as a promising alternative to the intramascular injection 
of naked DNA for genetic vaccination (Condon et al, 1996). Because of the easier 
physical accessibility the gene gun method has been widely applied for gene delivery 
to the skin and encouraging immune responses are reported in initial clinical studies 
(Tacket et al, 1999). 
Large amounts of DNA can be delivered by this method, however, the introduction 
of foreign materials such as gold particles, the relatively low transfection efficiency 
and possible physical damage to the cells remain disadvantages of the gene gun 
(Bleiziffer et al, 2007). 
3.3.1.2 Electroporation 
Electroporation is a method based on the administration of short (nanosecond range) 
high-voltage pulses to temporarily disrupt the cell membrane barrier (Gehl, 2003). 
The effect of the electric field disrupts the lipid and lipid-protein interactions and the 
membrane becomes porous and permeable, allowing reversible transitions (Neumann 
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et al, 1999). In short, cells and DNA are put into a cuvette in vitro and then placed 
between electrodes. After the electrical field is applied for a short incubation time to 
allow the DNA pass the cell membrane, cells are restored to normal culture 
conditions (Makrides, 2003). Cell size, temperature, post-pulse manipulation and 
composition of electrodes and pulsing medium are important parameters to be 
considered while performing electroporation (Gehl, 2003). Improved transfections 
for in vivo electroporation applications have been reported as electrochemotherapy, 
for the delivery of drugs and genes to malignant tumors, in brain (Nishi et al, 1997), 
skin (Dujardin et al, 2001) and muscle (Mir et al, 1999) tissues.  
Nevertheless, the need for a surgical procedure to place the electrodes into the organs 
(Gao et al, 2007) and the applied high voltage which results in inevitable tissue 
damage because of thermal heating (Durieux et al, 2004), limit the applicability of 
electroporation facilitated gene delivery methods 
3.3.1.3 Gene transfer by ultrasound radiation 
The first statement that ultrasound (US) may improve the transdermal penetration of 
drugs was established in 1954 (ter Haar, 2007). Following the developments in 
therapeutic applications of US, it was discovered that US waves can be used for gene 
transfer purposes both on the cellular (Kim et al, 1996) and tissue (Liang et al, 2004) 
levels. The term sonoporation is also used for this method, which is based on 
creating temporary plasma membrane defects by using US to generate acoustic 
cavitation (Mehier-Humbert and Guy, 2005). During each ultrasonic cycle, the tissue 
absorbs the energy of the propagating wave which results in thermal heating that 
affects the cell membrane structure (Al-Dosari and Gao, 2009). This way, the DNA 
can be transferred into the cytoplasm via passive diffusion through created 
membrane pores (Kim et al, 1996). The transfection efficiency of the system is 
controlled by the frequency, the output strength of the US wave, the duration of the 
treatment and the amount of the plasmid DNA used (Gao et al, 2007). 
The major improvement was observed in US mediated gene transfer when the 
technique was combined with contrast agents or microbubbles (Endoh et al, 2002). 
Microbubbles are compressible gas-field vesicles which are stabilized by surface 
active molecules such as cholesterol (Al-Dosari and Gao, 2009). Their ability to 
expand and shrink immediately under US application enhances the transfection 
23 
efficiency (Bao et al, 1997).  Furthermore, two successful in vivo examples can be 
stated for US-mediated gene delivery combined with a contrast agent: one of them 
with the aim of intravenous injection (Unger et al, 2001) and the second for 
disrupting the blood-brain barrier (BBB) (Sheikov et al, 2008). 
3.3.2 Viral vectors 
The use of viral vectors for gene delivery purposes has been the most efficient way 
(Loser et al, 2002). Viral particles contain a nucleic acid genome surrounded by a 
capsid of proteins. The introduction of a gene of interest into a host cell by a virus is 
defined viral transduction. They can easily gain entry to host cells where the genetic 
information is replicated by the host’s machinery. In the ideal case, these viral 
vectors utilize the viral infection pathway but avoid the subsequent expression of 
viral genes as this may lead to self-replication and potential toxic effects. Thus, the 
gene must be combined into a virus that is replication-deficient (Jang et al, 2004). 
There are large number of viral vector systems (i.e. retrovirus, adenovirus and adeno-
associated virus) used for gene therapy applications but the most frequently used 
adeno-associated virus  will be explained in this section. 
3.3.2.1 Adeno-associated virus 
Adeno-associated virus (AAV) is frequently chosen because it is able to transduce a 
variety of cells, including non-dividing cells, provide long-term gene expression, and 
offer minimalised immune response (Jang et al, 2004). However, applications are 
limited with AAV vectors due to a small packaging capacity, inefficient transgene 
expression and the need for duplication of the single-stranded DNA genome 
(Thomas et al, 2003). 
In addition to these issues, the reported failures of clinical trials with viral vectors 
accelerated the developments of safer, less pathogenic and immunogenic gene 
delivery alternatives such as non-viral vectors including lipid and polymer based 
delivery systems. 
3.3.3 Non-viral vectors 
Non-viral vectors have been developed as alternative gene delivery systems to viral 
vectors because they offer a number of potential advantages. These advantages can 
be listed as non-immunogenicity, ability for repeated administration, ease of 
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production and lower costs (Brown et al, 2001). The introduction of DNA by means 
of non-viral delivery system is defined as transfection process. This process includes 
a successful gene transfer and expression (Mountain, 2000). Most commonly used 
synthetic non-viral delivery systems will be described in the following. 
3.3.3.1 Lipid-based gene delivery systems 
Lipid-based systems have a variety of applications for drug and gene delivery in 
pharmaceutical industry. Liposomes are spherical bilayered phospholipid structures 
which are formed by the self assembly of a hydrophilic polar head group and 
hydrophobic hydrocarbon tail. In an aqueous media, this bilayered structure consists 
an internal aqueous phase and a water phase between the alternating bilayers 
(Remaut et al, 2007). Due to the earlier mentioned physicochemical characteristics of 
DNA molecule, cationic liposomes are the most frequently investigated carriers to 
encapsulate the anionic surface charge of DNA by electrostatic interactions. The 
cationic liposome and nucleic acid complexes are called as lipoplexes. 
Commonly used cationic lipids include N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-
trimethyl-ammoniumchloride (DOTMA) and 1,2-dioleoyl-3-
trimethylammoniumpropane (DOTAP) as illustrated in Figure 3.4. 
 
Figure 3.4 : Chemical structure of cationic lipid (A) DOTMA, (B) DOTAP and (C)   
an illustration of liposome, adapted from (Remaut et al, 2007). 
The use of lipids as gene delivery systems offers some advantages, such as their lack 
of immunogenicity which makes repeated delivery in vivo possible. Another 
advantage is the potential to deliver large amounts of DNA and the protection of 
DNA against physical forces and enzymatic degradation. However, there are some 
(B) 
(A) 
(C) 
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major limitations of these liposomes such as the duration and level of transgene 
expression (Brown et al, 2001). 
3.3.3.2 Polymer-based gene delivery systems 
As it was explained in the previous section that the understanding of the barriers that 
a vector system should overcome provides the development of safe and efficient 
vectors for the delivery of the plasmids. With this in mind, an ideal polymeric vector 
should meet the requirements of being able to neutralize the negative charge of the 
DNA to avoid charge repulsion against the anionic cell surface, to condense the 
DNA molecule to an appropriate length scale, and to protect the DNA from 
degradation by extracellular nucleases. Since cationic polymers are capable of 
condensing the negative charge of DNA, tremendous research has been done to 
improve their potential as non-viral gene carriers. They offer enhanced bio-safety 
and biocompatibility, a high flexibility regarding the size of the delivered nucleic 
acid, repeated administration and can be synthesized at low cost in large quantities 
(Wagner and Kloeckner, 2005). 
The nano-sized self assemblies of positively charged polymers and negatively 
charged DNA are defined as polyplexes (pplexes). The packaging of therapeutic 
genetic material by a cationic polymer can be based on three different ways including 
electrostatic interactions, encapsulation within the spherical polymer structure and 
adsorption onto biodegradable nanosphere (Wong et al, 2007).  
There have been many novel polymer structures developed for gene therapy 
applications but the most frequently investigated polymer systems include poly(L-
lysine) (PLL) (Pack et al, 2005), poly(ethyleneimine) (PEI) (Akinc et al, 2005), 
methacrylate polymers (Dubruel et al, 2003) and poly(amidoamine) (PAA) (Liu et al, 
2010), (See Figure 3.5). 
The ratio of amine groups present in the cationic polymer to phosphates on the 
plasmid affects the effective diameter and determines the surface charge of the 
polyplex. 
Poly(L-lysine) (PLL) was one of the first polycations used for polyplex formation. At 
physiological pH the amino groups of PLL are positively charged and interact 
ionically with the negatively charged phosphate groups of the DNA. 
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     Figure 3.5 : Chemical structures of selected polymers, adapted from (Wong et al, 
2007). 
PLL/DNA polyplexes have a highly positive zeta potential, interact electrostatically 
with a negatively charged cell surface, and are taken up by absorptive endocytosis 
(Wagner and Kloeckner, 2005). The efficiency of uptake can be enhanced by 
covalently coupling PLL with ligands that can specifically target cells and promote 
receptor-mediated uptake (Zauner et al, 1998). 
Poly(ethylenimine) (PEI) is an organic macromolecule with the highest cationic 
charge-density potential, allowing for a tight compaction of nucleic acids (Boussif et 
al, 1995). Linear PEI is solid at room temperature and contains only secondary 
amines, while branched PEI (bPEI) is liquid at all molecular weights and contains 
primary, secondary and tertiary amine groups (Ogris, 2004). Usually the branched 
form of PEI is used for gene delivery purposes. Because every third amino nitrogen 
atom is protonated, PEI has a buffer capacity at virtually any pH value (Boussif et al, 
1995).  
Methacrylate based polymers including poly(2-(dimethylamino)ethyl methacrylate)) 
(pDMAEMA) can be easily synthesized by radicalic polymerization. pDMAEMA 
apparently has advantageous properties to escape the endosome due to its average 
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pKa value of 7.5. This polymer is partially protonated at physiological pH and might 
behave as a proton sponge that can cause a disruption of the endosome, which results 
in the release of both the polyplexes and cytotoxic endolysosomal enzymes into the 
cytosol (van de Wetering et al, 1998). Moreover, pDMAEMA was shown to be an 
efficient vector for gene delivery to  OVCAR-3 cells (van de Wetering et al, 1999). 
Poly(amidoamine)s (PAAs) are synthetic tert-amino polymers obtained by stepwise 
polyaddition of primary or secondary aliphatic amines to bisacrylamides. Linear 
polymers are produced during the polymerization of both primary and secondary 
amines (Ferruti, et al, 2002). A novel bioreducible, disulfide containing family of 
PAAs were introduced by Lin et. al. (2007a). These polymers showed relative 
stability in physiological conditions but were rapidly degraded in reductive 
environment. SS-PAAs possessed higher buffer capacities than PEI in endosomal pH 
range, which may contribute to the endosomal escape of the polyplexes. Some 
members of SS-PAA family also showed higher transfection efficiency in COS-7 
cells than PEI with low cytotoxicity (Lin et. al, 2007a). Dendrimer form of 
polyamidoamines (PAMAM) also shows high transfection potential in the absence of 
any additional membrane-active agent. Due to the low pKa of its terminal and 
internal amines this polymer can act as an endosomal buffering agent by this way 
preventing DNA degradation within the endolysosomes (Wagner and Kloeckner, 
2005). 
A variety of polymer systems have been developed to maintain an efficient 
DNA/vector dissociation. These strategies include thermoresponsive polymers, 
bioreducible disulfide bonds and ester bonds (Wong et al, 2007). 
The polymeric gene delivery vectors have relatively low transfection efficiency when 
it is compared with viral and lipid based systems. Mainly, this delivery inefficiency 
of the polymeric vectors relies on their inability to overcome numerous barriers 
encountered between the site of administration and the localization of nucleus 
(Wiethoff and Middaugh, 2003). Thus, numerous strategies were applied to improve 
the efficiency of polymer vector systems. 
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4.  MATERIALS AND METHODS 
The aim of the research described in this work is to evaluate cationic polymers in 
terms of their physicochemical and biological suitability for gene therapy 
applications. For this purpose, non-biodegradable poly((2-dimethylamino)ethyl 
methacrylate) (pDMAEMA) polymer and bioreducible disulfide containing 
poly(amidoamine)s (SS-PAAs) were synthesized and evaluated. 
4.1 Polymer Synthesis 
4.1.1 Synthesis of pDMAEMA by radicalic polymerization 
As a leading compound, poly((2-dimethylamino)ethyl methacrylate) (pDMAEMA), 
is chosen as a candidate for gene delivery studies since it is relatively easy to obtain 
by radical polymerization from dimethylaminoethyl methacrylate (DMAEMA) and 
its molecular weight (Mw) can be controlled by controlling the amount of initiator 
and monomer. 
 
(4.1) 
DP = Degree of Polymerization (units of monomers in a polymer chain). 
[M] = concentration of monomer. 
[I] = concentration of initiator. 
Moreover, DMAEMA has amine groups which are protonated at physiological pH. 
Due to a neighboring effect present in the polymer, some groups remain 
unprotonated and therefore enable the polymer to express buffering capacities. In 
gene therapy, the buffering capacity of a polymer is extremely important as it enables 
the polymer to escape from endosomes.  
The low Mw pDMAEMA (50 kDa) and high Mw pDMAEMA (600 kDa) which are 
evaluated in this thesis were obtained from Ghent University Polymeric Biomaterials 
Group (Ghent, Belgium). 
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Figure 4.1 : Chemical structures of  a. DMAEMA monomer, b. pDMAEMA 
polymer. 
The synthesis of pDMAEMA (250 kDa) was performed by thermally initiated 
radicalic polymerization reaction, as a model reaction for this study.  
It should be noted that even though the general set up and mechanisms are the same 
for low and high Mw pDMAEMA synthesis, it is not possible to synthesize high Mw 
pDMAEMA with the same initiator. As it was previously stated by van de Wetering 
et. al., high Mw (>300 kDa) pDMAEMA polymers were obtained when ammonium 
persulfate (APS) radicalic initiator was used in aqueous solution conditions (1998). 
As it is illustrated in Figure 4.2, the AIBN initiator splits into two radical molecules 
in the initiation step. Afterwards, the propagation occurs while the radical attacks to 
the DMAEMA monomer. Then the monomer radical attacks to the other DMAEMA 
monomer and the polymerization continues by the formation of polymer radicals. 
The termination of the polymerization can be either via combination of two radicalic 
polymers with each other or disproportionation. 
The DMAEMA monomer is commercially available from Fluka Analytical 
(Belgium). The pDMAEMA polymer was synthesized according to a previously 
published protocol (Dubruel et al, 2000). In short, first the monomer is stabilized 
with inhibitors and it is necessary to carry out a vacuum distillation prior to 
polymerization. Therefore, the monomer was vacuum distilled for 2 hours. Although 
it contained polymerization inhibitor, 10% of the monomer was polymerized and 
sticked to the flask. At the end of the distillation, the distilled monomer liquid was 
decanted gently from the flask. 
a.  b. 
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Figure 4.2 : Illustration of radicalic polymerization reaction  mechanism. 
AIBN 
DMAEMA 
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        Figure 4.2 (continued) : Illustration of radicalic polymerization reaction  
mechanism. 
Meanwhile, the solvent of the reaction was distilled nearly for 3 hours in order to get 
rid of any possible impurities. The solvent purification was performed in the 
presence of Ca(OH)2 to dry out existing water or moisture in the solvent.  The choice 
of the solvent and initiator depends on the solubility of the monomer as well as the 
polymer which will be synthesized inside and the desired Mw of the polymer. As an 
appropriate solvent, both for monomer and polymer, toluen was used and azo-bis-
isobutyronitrile (AIBN) was chosen as an initiator for the polymerization reaction.  
Prior to polymerization, a cooler, a valve and a two neck, round-bottomed flask were 
put in the drying oven, to remove any possible moisture. Firstly, the flask was placed 
in an oil bath which was placed on a magnetic stirrer, to allow monitoring of both the 
temperature and the stirring speed. Secondly, the reflux cooler was fixed to the flask 
and above this cooler the valve was placed with a connection to a balloon filled with 
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N2. The other neck of the flask was covered with a septum to avoid air-contact. 
Finally, after addition of monomer and solvent, all contacts and seals were checked. 
Before and after the addition of the appropriate amount of initiator, the reaction 
mixture is degassed and purged with N2, by means of a vacuum pump and a balloon 
filled with N2. This procedure was performed in order to remove the O2 present in the 
set up as it may disturb the polymerization due to trapping of initiator radicals 
(Osinglet – Otriplet transition) which may lead to the absence of the initiator-propagation 
transition (Cherng et al, 1996). 
When all of the reagents were purified and ready for the synthesis, the reaction was 
started by adding the calculated amounts of reagents according to the desired Mw of 
polymer. . A Mw of 250 kDa (250000 g/mol) was desired, 7.74 mg of AIBN was 
added to 10 % DMAEMA (25.3 mL) in toluene as shown by the following 
calculation. The density and Mw of DMAEMA are 0.93 g/ml and 157.21 g/mol 
respectively. The Mw of AIBN is 164.21 g/mol. Based on these values, the following 
calculations were made : 
Aimed DP = Mw polymer / Mw monomer 
                  = (250000g/mol) / (157.21g/mol) = 1590.23 units   
Amount of monomer : If we start with 0.15 moles of monomer [M], 
 ;   
0.15 mol = m monomer / 157.21g/mol 
m monomer = 23.58 g  
 ; 
0.93 g/ml = 23.58 g / Vmonomer 
Vmonomer = 25.3 mL 
Amount of initiator : [I] = [M]/ DP 
[I] = 0.15 mol / 1590.23 = 9,43 x 10
-5
 mol 
minitiator  = [I] x Mw  
minitiator  = 9,43 x 10
-5
 mol x 164,21 g/mol = 0,01548 g 
At the initiation step of the reaction, as every 1 mole of initiator gives rise to 2 moles 
of radicals as illustrated in figure 4.2, the calculated amount of the initiator should be 
divided by 2. This results in, 0.01548 g / 2 = 0.00774 g = 7.74 mg of AIBN. 
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After the addition of AIBN the polymerization reaction is started by heating the oil 
bath to approximately 75⁰C, in order to obtain a temperature of 65 - 70⁰C in the 
flask, for 24 hours. 24 hours later, the polymerization reaction was stopped and the 
obtained reaction mixture is brought to room temperature. The mixture in toluene 
was precipitated drop wise in ice-cooled distilled pentane (5x volume of the reaction 
mixture). As a non-polar solvent pentane can remove the solvent of the reaction 
(toluen), the residue of the monomer (DMAEMA) and the initiator (AIBN). The 
synthesized polymer was separated from the pentane by decantation. After the 
precipitation procedure, a sticky and gummy polymer was obtained. Then the 
polymer was left to be dried and re-precipitated in ice-cooled ultra pure acetone (5x 
volume of the reaction mixture) and again it was left to be dried. Finally, the polymer 
was dissolved in ultrapure water. To ensure a good dissolution of the polymer in 
water, a few drops of 0,5 M HCl are added. This solution was purified by dialysis 
through a membrane with a Mw cut-off of approximately 1/5
th
 of the Mw of the 
polymer. The dialysis procedure was carried out for 48 hours against ultrapure water, 
0,1 M NaCl solution and 0,1 M HCl solution respectively. Subsequently, the 
dialyzed polymer solution was freeze-dried, then the final product was characterized 
by NMR (300 MHz, CDCl3, relative to TMS) and stored at -20⁰C for further 
experiments.  
p(DMAEMA): 1H-NMR (CDCl3) δ (ppm) = 1.83 (CH3C(CH2)CH2); 1.92 
((CH3)CCH2C(CH3)); 2.29 (CH2N(CH3)CH3); 2.57 (CH2N(CH3)CH3); 4.06 
(O=COCH2CH2). 
4.1.2 Synthesis of SS-PAAs by Michael-type polyaddition 
Poly(amidoamine)s (PAAs) have attracted significant interest due to their 
biocompatibility and biodegradability as potential gene delivery systems. A new 
series of PAAs containing repetitive disulfide linkages (SS-PAAs) in the polymer 
backbone was previously introduced by Lin et. al. (2007a). Moreover, Zintchenko 
et.al. have reported an improved synthesis strategy for SS-PAAs by means of Ca
2+ 
catalysis in order to increase polymerization times of conventional synthesis (2011). 
In this study, three types of SS-PAAs were synthesized by Ca
2+
 catalyzed Michael 
type polyaddition of a primary amine to N,N’-cyctaminebisacrylamide (CBA) 
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monomer according to published protocol (Zintchenko et al, 2011). The 
polymerization reactions are illustrated in following figures (Figure 4.3, 4.4, 4.5) : 
 
 
     Figure 4.3 : Illustration of Michael type polyaddition of a primary amine to 
bisacryl amide monomer, adapted from (Lin et al, 2007a). 
      
 
      Figure 4.4 : Illustration of Michael type addition polymerization of a. p(CBA-
ABOL), b. p(CBA-HIS), adapted from(Coue and Engbersen, 2011). 
 
All monomers, 4-amino-1-butanol (ABOL, Aldrich), histamine (Fluka), N,N’-
cystaminebisacrylamide (CBA, polysciences, USA), were purchased in the highest 
purity and no further purification was used. All reagents and solvents were of reagent 
grade and were used without further purification.  
Solutions of CaCl2 in methanol and in water (0.4 M) were prepared separately and 
mixed together at the ratio of 3/1 (v/v) just before the synthesis. The polymerizations 
were carried out with 1:1 molar ratio between the reactants. 
CBA a primary amine              Poly(amidoamine) 
CBA ABOL 
CBA HIS 
a. 
b. 
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        Figure 4.5 : Illustration of Michael type addition polymerization of a p(CBA-
ABOL/DMEDA/PEG) copolymer, adapted from (Vader et al, 
2012). 
Solutions of CaCl2 in methanol and in water (0.4 M) were prepared separately and 
mixed together at the ratio of 3/1 (v/v) just before the synthesis. The polymerizations 
were carried out with 1:1 molar ratio between the reactants. As a typical reaction 
ABOL (0.34 g, 3.85 mmol ) was added to CBA (1.0 g, 3.85 mmol), 2 ml of solvent 
was added, and the reaction flask was sealed. The polymerization was performed at 
50⁰C and the reaction was allowed to proceed for 30 h, yielding a viscous solution. 
Subsequently, the polymerization was quenched with 10 mol% excess of ABOL 
(0.034g, 0.385 mmol) in order to consume any unreacted acrylamide groups and 
stirring was continued for 1 h at 50⁰C. The resulting solution was diluted with water 
to about 20 ml, acidified with 6 M HCl to pH ~ 4, and then purified using a 
ultrafiltration membrane (MWCO 1000 g/mol). After freeze-drying, the p(CBA-
ABOL) polymer was collected as its HCl–salt form. The same procedures were 
applied for the synthesis of p(CBA-HIS) polymer. The p(CBA-
ABOL/DMEDA/PEG) polymer was obtained from Engbersen Lab. (University of 
Twente, The Netherlands). The polymerization of PEGylated p(CBA-ABOL) was 
also performed with the same procedure. The Michael type addition of ABOL and 
PEG-NH2 to CBA was followed by a second addition of DMEDA monomer as 
illustrated in figure 4.5. 
NMR spectra of final products were recorded on Varian Unity 300 (
1
H NMR 300 
MHz) using tetramethylsilane (TMS) as the internal standard.  
CBA 
ABOL 
PEG-NH2 
DMEDA p(CBA-ABOL/DMEDA/PEG) 
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p(CBA-ABOL) : 
1
H NMR (D2O) δ (ppm) = 1.73 (CH2CH2OH, 2H); 1.94 
(CH2CH2CH2OH, 2H); 2.91(2 × NHCOCH2, 4H); 3.00 (2 × SSCH2CH2, 4H); 3.36 
(NCH2CH2CH2CH2OH, 2H); 3.59 (CH2CH2NCH2CH2, 4H); 3.66 (2 × SSCH2CH2, 
4H); 3.75 (CH2OH, 2H), 4.90 (2 x NH, 2H) .   
p(CBA-HIS) : 
1
H NMR (D2O) δ (ppm) = 2.77 (2 × NHCOCH2, 4H); 2.95 (2 
× SSCH2CH2, 4H); 3.17 (NCH2CH2, 2H); 3.38 (CH2N(CH2)CH2, 6H); 3.61 (2 × 
SSCH2CH2, 4H); 7.26 (C=CH–N, 1H); 8.38 (C–N=CH–N, 1H). 
The molecular weight and polydispersity (Mw/Mn) of the synthesized SS-PAAs 
were determined by gel permeation chromatography (GPC) relative to PEO 
standards (Polymer Labs) as suggested by Jiang et.al. (2006). A Viscotek GPCMax 
pump, autoinjector and two thermostated (30°C) PL aquagel-OH 30 columns (8 μm, 
300×7.5 mm, Polymer Labs, with a low-molar-mass separation range 200 – 40,000) 
were used during the analysis. Data were collected using a TDA302 Tripledetector 
with RI, Visc and LS (7 and 90°). 0.3 M NaAc aqueous solution, pH 4.4, with 30% 
methanol was used as eluent at a flow rate of 0.7 ml/min). 
4.2 Cell Culture 
In this project, in vitro studies were done with ARPE-19 cells (retinal pigment 
epithelial cell line; ATCC number CRL-2302), which are described by Dunn et al. as 
an adherent, human retinal pigment epithelium (RPE) cell line (1996). 
4.2.1 Materials 
Dulbecco’s modified Eagle’s medium (DMEM), serum-free transfection medium 
OptiMEM™, L-glutamine, fetal bovine serum (FBS), penicillin-streptomycin 
solution (5000 IU/mL penicillin and 5000 μg/mL streptomycin) (P/S), and 
phosphate-buffered saline (PBS) were provided from GibcoBRL (Merelbeke, 
Belgium). Trypsin was purchased from Sigma Aldrich (Bornem, Belgium) and used 
as 0.05% trypsin/ 0.02% ethylenediaminetetraacetate (EDTA) solution. 
4.2.2 Methods used in cell culture 
The cells are grown in polystyrene (PS) culture bottles in RPE cell culture medium 
(CCM), (DMEM:F12 supplemented with 10% fetal bovine serum (FBS), 2 mM          
38 
l-glutamine, and 1% penicillin/streptomycin (P/S)), and incubated at 37⁰C and in the 
presence of 5% CO2 (Nu-5510 NuAire incubator). 
All cell work is done under sterile laminar airflow conditions. When the monolayer 
of ARPE-19 cells has become 70-80 % confluent in culture bottle, the cell line is 
spliced to a new cell culture bottle. Prior to cell splicing procedure, the cells are 
always checked under the microscope for possible contamination. First of all, the old 
CCM is removed to waste. Then the cells are washed once with PBS solution without 
Ca
2+
 and Mg
2+
, to get rid of the dead cells floating inside the bottle and any 
remaining serum, which might inhibit trypsin activity. Afterwards, the flask is 
shaken gently and the PBS is aspirated from the bottle. Secondly, the cells are 
trypsinized with pre-warmed trypsin/EDTA solution and incubated at 37⁰C for 5 
minutes. Trypsin provides the cell detachment from the bottle surface and EDTA 
chelates the remaining divalent cations, necessary for Ca
2+
-dependent cellular 
adhesion molecules. When cell detachment is verified by light microscopy, trypsin is 
neutralized and inhibited by means of pre-warmed fresh CCM since the serum in the 
CCM contains trypsin inhibitors. Fourthly, a certain amount of cell suspension is 
transferred to a new culture bottle. Then the cells are re-incubated at 37⁰C and in the 
presence of 5% CO2 until the next passage. If the cells are needed the next day for a 
transfection experiment, then the cells are counted, seeded and plated following the 
trysinization step. 
4.3  Nucleic Acids Used in This Study  
4.3.1 pGL4.13 plasmid 
Bacterial plasmids are described as closed circular molecules of double-stranded 
DNA. Their size can range between 1-200 kb. There are genes which code for 
enzymes in plasmids. pGL4.13 is a plasmid of the series of pGL4-luciferase reporter 
vectors of Promega (Leiden, The Netherlands). It encodes for luciferase reporter 
gene (luc2) and is designed for high expression and reduced anomalous transcription. 
Besides, the genes of pGL4.13 plasmid encodes for ampicilline (Amp
r
) resistance 
(See Figure 4.6).  
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During this thesis study, pGL4.13 plasmid is isolated from Eschericia Coli bacteria 
by using Qiafilter Plasmid Purification Kit (Qiagen, Venlo, The Netherlands) 
according to the instructions manual. 
 
Figure 4.6 : Schematic representation of pGL4.13 plasmid. The plasmid encodes for 
luc2 gene under the control of SV40 promoter. Amp
r
: ampicilline 
resistance marker [Url-4]. 
This assay is based on growing the bacteria containing the plasmid in appropriate 
medium and then isolation of the plasmid from the grown bacteria culture. The 
isolation includes filtration of alkaline lysate of the bacteria, centrifugation of lysate, 
anion-exchange chromatography for selective isolation of pDNA from lysate and 
finally purification of plasmid by alcohol precipitation (QIAGEN, 2005). The 
concentration and purity of isolated pDNA were determined by measuring the UV 
absorption at 260 and 280 nm with Nano Drop 2000c UV-Vis Spectrophotometer 
(Thermo Scientific, USA). Subsequently, pDNA solution was diluted to 1 mg/ mL 
and stored at -20⁰C. 
4.3.2 gWiz™-GFP plasmid 
The gWiz™-GFP plasmid which encodes for green fluorescent protein is an 
expression vector from the gWiz™ series of Aldevron (Freiburg, Germany). As a 
bacterial selection marker, kanamycin (kan
r
) resistance was used in this plasmid. The 
gWiz™-GFP plasmid is designed for the highest level of gene expression in various 
types of mammalian cells and tissues (See Figure 4.7). In this study, transfection 
efficiency studies were analyzed in terms of GFP expression by the use of gWiz™-
GFP plasmid. 
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     Figure 4.7 : Schematic representation of gWiz™-GFP plasmid. kanr: kanamycin 
resistance [Url-5]. 
4.3.3 YOYO
®
-1 iodide labeled pGL4.13 plasmid 
For uptake efficiency purposes, pGL4.13 plasmid was fluorescently labeled with 
YOYO
®
-1 iodide dye (λex = 491 nm, λem = 509 nm). This is a green fluorescent dye 
from a series of dymeric cyanines obtained from Molecular Probes (Merelbeke, 
Belgium). The plasmid and YOYO-1 (1 mM in DMSO) iodide was mixed at a ratio 
of 0.15/1 (v/w), to provide a theoretical labeling density of 1 YOYO-dye molecule 
per 10 bp. Then the mixture was incubated at room temperature for 4 h in the dark. 
Free YOYO-1 dye and DMSO were removed by precipitating the labeled plasmid. 
For this purpose 2.5 volumes of ice-cold ethanol and 0.1 volume of 5 M NaCl were 
added to the plasmid/YOYO-1 solution. After incubation for 30 min at -80°C, the 
centrifugation (17000 g, 30 min) and washing with clean 70 % ethanol, fluorescently 
labelled plasmid was finally resuspended in 25 mM HEPES, pH 7.2. The 
oncentration of the plasmid was again determined by UV absorption at 260 and 280 
nm with Nano Drop 2000c UV-Vis Spectrophotometer (Vercauteren et al, 2011). 
4.4 Preparation and Physicochemical Characterization of Polyplexes  
4.4.1  Dynamic light scattering 
4.4.1.1 Theory and working principle  
Dynamic Light Scattering (DLS) is a technique which is used to measure the size-
related Brownian motion of particles. Particles suspended within a liquid will move 
randomly under influence of the surrounding solvent molecules. The larger the 
particle, the slower the movement will be. The translational diffusion coefficient D is 
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a measure for the diffusional motion, from which the hydrodynamic diameter is 
calculated by using the Stokes-Einstein equation (4.2) :  
 (4.2) 
where:  
d(H) = hydrodynamic diameter (m)  
D = translational diffusion coefficient (m².s-1)  
K = Boltzmann’s constant (1.38 x 10-23 m².kg.s-2.K-1)  
T = absolute temperature (K)  
η = viscosity (kg.m-1.s-1)  
The diameter that is obtained by DLS is the diameter of a sphere that has the same 
diffusion coefficient as the measured particle. This coefficient will depend not only 
on the size of the particle core, but also on any surface structure, as well as the 
concentration and type of ions in the medium.  
The Brownian motion of particles is measured by determining the rate at which the 
intensity of light, scattered from the particles, fluctuates when detected with a 
suitable optical arrangement. The signal intensities at different time points are 
compared and a correlogram is constructed by a digital auto correlator in the DLS 
machine. This device will also determine the correlation function of the scattered 
intensity, from which the size of the particles can be calculated by using a suitable 
algorithm. The size distribution obtained from the DLS measurements is a plot of the 
relative intensity of light scattered by particles of various sizes and is therefore an 
intensity-dependent size distribution. 
The other important parameter that determines the stability of nanoparticles is zeta 
potential which is defined as the measure of the magnitude of the electrostatic or 
charge repulsion or attraction between particles. Its measurement gives detailed 
information about the causes of dispersion, aggregation or flocculation, and can be 
used to improve the formulation of dispersions, emulsions and suspensions. When 
charged surfaces are put in aqueous solution an electric double layer forms at the 
particle-liquid interface. The electric double layer consists of two parts: an immobile 
layer of adversely charged ions where in this Stern layer the ions are bound tightly to 
the surface. Secondly, there is an outer layer, which is a diffuse layer where a 
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balance of electrostatic forces and random thermal motion determines the ion 
distribution. The potential in this region, therefore, decays with increasing distance 
from the surface until, at sufficient distance, it reaches the bulk solution value, 
conventionally agreed to be zero as illustrated in figure 4.6. The magnitude of the 
zeta potential gives an idea about colloidal stability of the suspension. If all the 
particles have a large value of positive or negative surface charge, then they will tend 
to repel each other and there will be no tendency for the particles to come together 
and form aggregates. In reverse case, if they have a low zeta potential then there will 
be no force to prevent the particles floculating. The main factors that affect the zeta 
potential of a particle can be stated as pH of the solution, conductivity and 
concentration of a formulation component (See Figure 4.8). 
 
Figure 4.8 : Schematic illustration of zeta potential [Url-6]. 
 
 The measurement of the zeta potential was performed on a Zetasizer. This apparatus 
calculates the zeta potential by determining the electrophoretic mobility (μ) of the 
polyplex. The latter is obtained by measuring the velocity of particles using Laser 
Doppler Velocimetry (LDV). The velocity and electrophoretic mobility are related 
by the following equation (4.3) : 
 (4.3) 
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By applying the Henry equation the zeta potential can be calculated from the 
following formula (4.4) :  
 (4.4) 
where;  
μ = the electrophoretic mobility in m2/Vs 
ζ = the zeta potential in V 
 = the dielectric constant in F/m 
 = the viscosity of the medium in cP 
f(ka) = Henry’s function 
In this project, a Nano-ZS (Malvern Instruments, Hoeilaart, Belgium) is used for 
DLS measurements. This instrument consists of the following main components (See 
Figure 4.9) : a laser beam (1) illuminates the sample contained in a cell (2). To 
prevent that the detector becomes saturated or that an insufficient amount of light 
reaches the detector, a variable attenuator (4) is placed between the laser and the 
sample, allowing to reduce or increase the intensity of the laser source and hence the 
intensity of scattering. The laser beam is scattered by the particle within the sample 
at all angles and a detector (3) measures the scattered light. In the Nano-ZS model, 
the detector is positioned at 173°. The signal from the detector is then passed to a 
correlator (5) that compares the scattering intensity at successive time intervals to 
derive the rate at which the intensity is varying. The information obtained by this 
digital processing board is then passed to a computer, equipped with Nano software 
to analyze the data and derive size information. 
4.4.1.2 Particle size and surface charge measurements 
All DLS measurements were performed in triplicate on a Nano-ZS (Malvern 
Instruments, Hoeilaart, Belgium), equipped with an Argon laser beam (488 nm) at a 
scattering angle of 173° and a temperature of 25°C. The preparation of polyplexes 
occurs as described in the following section. 
4.4.2 Preparation of polyplexes  
Polymer/DNA complexes were obtained by mixing the cationic polymer solution and 
anionic pDNA as illustrated in Figure 4.10. 
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      Figure 4.9 : Main components and optical configurations of a Nano Ζeta-sizer 
instrument for DLS measurements [Url-7]. 
The formation of polyplexes are spontaneous and depends on electrostatical 
interaction between polymer and pDNA. All the polyplexes in this study were 
prepared in a filtered (0.2 μm mesh size), 25 mM, pH 7.2 HEPES buffer solution 
under dust-free laminar air flow conditions. 
4.4.2.1 pDMAEMA polyplexes 
pDMAEMA polyplexes were prepared with two different polymer Mw 50 kDa and 
600 kDa, and in two different polymer/pDNA mass ratios of 1.5/1 and 12/1. As 
plasmid DNA, pGL4.13 plasmid is used for all DLS measurements in this thesis. The 
DLS samples with different polymer/pDNA mass ratios were prepared with changing 
amounts of polymer but the same amount of plasmid (10μL). The polymer stock 
solution (5 mg/mL) was diluted in HEPES buffer solution to have a concentration of 
0.6 mg/mL. The pDNA stock solution (1mg/mL) was also diluted until a 
concentration of 0.05 mg/mL. Then the formation of polyplexes were achieved 
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Figure 4.10 : Formation of polymer/DNA nanocomplex (polyplex) by self-assembly, 
adapted from (Coue and Engbersen, 2011). 
by mixing the appropriate amount of polymer with pDNA solution which 
corresponds to 10 μg of plasmid. The amount of polymer for each ratio was 
calculated as follows :   
(1.5/1)  Polyplex preparation : 
 
M1.V1 = M2.V2 
 
8.33x dilution of polymer stock (100 μL polymer + 733 μL HEPES) 
                     -> 5 mg/mL x 100 μL = M2x 833 μL 
                                  M2 = 0,6 mg/mL 
 
20x dilution of pDNA stock (10 μL pDNA + 190 μL HEPES) 
                     ->  1 mg/mL x 10 μL = M3 x 200 μL 
                                   M3= 0,05 mg/mL 
 
Add 25 μL of 0,6 mg/mL polymer to 200 μL of 0,05 mg/mL pDNA then dilute to 
1ml with 775 μL HEPES. 
                      
1.5/1 polyplex contains:  
                                    [(5μg/μLx 100 μL) x 25/833] = 15 μg of polymer 
                  (1μg/μL x 10 μL) = 10 μg of pDNA 
(w/w) ratio -> 15 μg / 10 μg = 1.5/1 
When the polyplexes were formed after 20 minutes, first of all the particle size and 
polydispersity index (pDI) of the samples were measured in low volume polystyrene 
(PS) cuvettes to avoid any electrical effect that may disturb the polyplex formation. 
Subsequently, ζ-potential measurements were performed in clear disposable zeta 
cells.  
Additionally, prior to the in vitro evaluation studies which are performed in 
OptiMEM™ GibcoBRL (Merelbeke, Belgium) serum free transfection medium, the 
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particle size and pDI measurements were also applied for the polyplexes in 
OptiMEM, representative for the stability in physiological media. For this purpose, 
polyplexes were prepared in the previous way but after the polyplex formation in 
HEPES, polyplexes were diluted 2 times in OptiMEM. Since OptiMEM media is rich 
in different types of proteins and dissolved ions, charge measurements were not 
carried out in OptiMEM media. 
4.4.2.2 SS-PAA polyplexes 
The polyplexes with p(CBA-ABOL), p(CBA-ABOL/DMEDA/PEG) and p(CBA-
HIS) polymers were prepared in the same way as the pDMAEMA polyplexes were 
done. The amounts of polymers and pDNA that are calculated for polyplex formation 
are shown as a model for 48/1 ratio below : 
48/1 (polymer/pDNA) polyplex preparation : 
 
M1.V1 = M2.V2 
 
8.33x dilution of 5 mg/mL polymer stock (100 μL polymer + 733 μL HEPES) 
                     -> 5 mg/mL x 100 μL = M2x 833 μL 
                                  M2 = 0.6 mg/mL 
 
20x dilution of 1 mg/mL pDNA stock (10 μL pDNA + 190 μL HEPES) 
                     ->  1 mg/mL x 10 μL = M3 x 200 μL 
                                   M3= 0.05 mg/mL 
 
Add 800 μL of 0,6 mg/mL polymer to 200 μL of 0,05 mg/mL pDNA. 
                      
48/1 polyplex contains:  
                                      [(5μg/μL x 100 μL) x 800/833] = 480 μg of polymer 
                    (1μg/μL x 10 μL) = 10 μg of pDNA 
  
(w/w) ratio -> 480 μg / 10 μg = 48/1 
For HA-coated p(CBA-ABOL) polyplexes, research grade HA with a known Mw 
range of 20-40 kDa was purchased from Lifecore Biomedical (MN, U.S.A). The 
chosen optimum polymer/pDNA ratio 48/1 was applied for the preparation of 
polyplexes. Polyplexes with 48/1 ratio were prepared as previously explained. When 
the polyplexes were formed, HA-coating was performed on 200 μL pplx 
(corresponding to 2 μg pDNA), with varying amounts of HA for the same amount of 
pDNA. Afterwards, the polyplex-HA mixture was vortexed for 10 seconds and 
allowed to stabilize for 15 minutes. Particle size and polydispersity of HA-coated 
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polyplexes were measured both in HEPES and OptiMEM™ media. As is mentioned 
before, the ζ- potential is only measured for the complexes in HEPES. 
For 25.5/1 (HA/pDNA) ratio : 
 
12,4 μL of 5 mg/mL stock HA solution is diluted to 800 μL with HEPES 
 
                     5 mg/mL x 12.4 μL = 62 μg HA  
                      
Mw HA = 402 g/mol 
Mw pDNA = 330 μg/μmol 
  
Molar ratio (HA/pDNA) -> (62 µg / 402 µg/µmol) / (2 µg / 330 µg/µmol) = 25.5/1 
4.4.3 Agarose gel electrophoresis 
4.4.3.1 Principles  
Gel electrophoresis is a technique in which a gel matrix and an electric field are used 
to separate molecules based on their size and surface charge. DNA molecules will 
migrate to the positively charged electrode when forced over a gel by an electric 
current due to the negative charge on their phosphate backbone. Larger molecules 
will migrate more slowly because they move less easily through the gel network. 
After the separation is completed, the DNA fragments can be visualized with 
ethidium bromide, a fluorescent dye that intercalates between the heterocyclic bases 
in DNA helixes. This intercalation strongly intensifies the signal obtained when the 
gel is exposed to UV light. Thus, different DNA fragments in the sample can be 
distinguished and their size can be determined by adding a DNA ladder (a sample 
containing different DNA molecules of known size) on the gel in parallel with the 
unknown sample.  
In this study, agarose gel electrophoresis was used as a tool in determining the pDNA 
condensation ability of polymers and optimal polymer/pDNA ratio for polyplex 
formation. It allows to detect if there is still uncomplexed DNA present in the 
samples after complexation. If so, a migration band located toward the positive 
electrode will clearly be visible after electrophoresis. Usually, free pDNA is added to 
the gel to confirm the band in the polyplex well indeed corresponds to free pDNA. 
As this is unwanted, this indicates that a higher polymer ratio is needed to form 
stable polyplexes. 
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4.4.3.2 Experimental part 
To visualize the pDNA complexation ability of polymer, polyplexes were applied on 
agarose gel electrophoresis. 
For the preparation of TBE Electrophoresis buffer; 10.8 g/L Tris-base (Sigma, 
Bornem, Belgium), 2.5 g/L Boric acid (Merck, Brussels, Belgium) and 0.58 g/L 
EDTA (Titriplex®; Merck, Brussels, Belgium) were dissolved in double distilled 
water.  
A 1% agarose gel was prepared using electrophoresis grade agarose powder 
(Invitrogen, Merelbeke, Belgium) and 10x TBE electrophoresis buffer (10 mL buffer 
in 100 mL water). The powder was dissolved by heating the suspension to 90°C in 
microwave. When the agarose was completely dissolved, the solution was cooled 
down till approximately 50°C, then solution was poured into a gel casting tray 
containing a sample comb and was allowed to solidify at room temperature. The 
solution is left to solidify gently at room temperature, to prevent clumping inside the 
agarose network. 
In the meantime, the complexes were prepared with the appropriate ratios as 
explained in section 4.2.2. Then 20 μL samples (including 0.2 μg pDNA) were taken 
from each polyplex solution. The samples were mixed with 5μL loading buffer (50% 
sucrose solution in TBE) containing bromophenol blue as colorant. The loading 
buffer makes the samples more dense to remain at the bottom of the gel lane and 
bromophenol blue present in the loading buffer helps to visualize the migration of the 
complexes. 
When the gel was formed, the polyplex samples were loaded into gel, and subjected 
to electric field at 100 V for 40 minutes in 1x TBE buffer. 1 kbp DNA ladder 
(BIORON) was added as a Mw marker and pure pGL4.13 plasmid as a reference 
were applied into gel. Heparin, as a molecule with the highest known anionic charge 
density was used as a control for DNA displacement. After that, the gel was stained 
by incubation on ethidium bromide (EtBr) bath for ±1 hour. Subsequently, the gel 
was observed by UV-illumination. At last, the photograph of the gel was recorded by 
a camera and processed by the software (Kodak Digital Sicence).  
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4.5 In vitro Biological Evaluation of Polyplexes 
The major goal of gene therapy is the introduction of a vector carrying the gene of 
interest into cells and to allow these cells to express that specific gene. Besides, 
during this transfer process, the carrier should not harm the exposed cells. In this 
study, after the polymer/pDNA complexes were investigated for their stability and 
DNA condensation ability, it is aimed to evaluate the synthesized polymers by means 
of their cellular uptake and gene expression efficiencies as well as the viability 
response of the ARPE-19 cells to the introduction of cationic vectors synthesized in 
this thesis.  
4.5.1  Flow Cytometry 
4.5.1.1 Principles 
Flow cytometry is a technique that is capable of performing simultaneous 
measurements such as counting, examining and analyzing cells in a flowing 
suspension depending on the certain chemical and physical properties of cells. With a 
flow cytometer, a cell suspension is analyzed cell per cell using a capillary tube 
through which the cell suspension passes along a laser beam that is perpendicular to 
the capillary tube (See Figure 4.11). The instrument can measure up to 3000 cells 
passing in the capillary tube per second. The laser light is scattered in the forward 
(forward scatter, FS) and sideward scatter (SS) direction, and by using a combination 
of dichroic mirrors and filters, fluorescence emission light is sent to individual 
detectors and in different spectral channels. The detectors convert the optical signal 
to an electrical signal. The scatter signal is used to derive information on cell size 
and granularity, while fluorescence is used to obtain additional information, such as 
uptake and transfection efficiency of the non-viral particles which are being 
evaluated.  
The equipment contains 3 subsystems: fluidics, optics and detectors. In the fluidics-
subsystem, a stream of cells is introduced into the flow and prepared for single cell 
measurement. This is done by hydrodynamic focusing: pressure causes the sheath 
buffer to be driven through a flow cell. The sample stream, entering the system 
between two sheath buffer streams, is compressed by these surrounding streams, 
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which causes the arrangement of the cells in the sample like pearls on a string. This 
way, the cells are passed through the flow cell one at a time. 
 
Figure 4.11 : The scattering of laser in flow cytometer [Url-8].   
4.5.2 Uptake and transfection efficiency studies 
For uptake and transfection efficiency studies cells were seeded as follows: after  the 
trypsinization of the ARPE-19 cells, the cells were counted with Burker Counting 
Chamber and diluted to a concentration of 10x10
4 
cells per mL. Then cells were 
seeded into 12-well plates with a confluence of 10x10
4
 cells per well (2,5x10
4 
cells 
per cm
2
, 1 mL of diluted cell suspension). Next, they were allowed to attach on the 
plate overnight. The day after, CCM was removed from the wells and freshly 
prepared polymer/pDNA complexes in OptiMEM were added to the cells, with a 
pDNA concentration of 2 μg per well (for polyplex preparation see section 4.4). 
During the uptake experiments, YOYO-1 labelled pGL4.13 plasmids were used for 
the preparation of the polyplexes. One set of the cells with the same polyplexes were 
put at 4⁰C as it is known that 4°C almost completely inhibits cellular uptake. After 2 
h incubation, the extracellular fluorescence of the cells, caused by the fluorescent 
polyplexes attached to the cell surface but not taken up, was quenched with trypan 
blue (0,20%) for 5 minutes at RT after which the cells were washed with PBS. 
Subsequently, they were detached by trypsinization. When they were loosened 
enough, cell pellets were collected by centrifugation for 7 min at 300g. Prior to the 
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measurements, the cells were resuspended in flow buffer (PBS with 0,1% azide, 1% 
BSA).  
For transfection experiments, the gWiz™-GFP plasmid was used which expresses 
the green fluorescent protein (GFP) and enables the quantification of a green 
fluorescent signal in ARPE-19 cells. Non-treated cells and the cells which were 
transfected with non-fluorescent pGL4.13 plasmid were negative controls for 
transfection experiments. 2 hours after the addition of polyplexes, the complexes 
were removed and cells were incubated 22 h more in full CCM. After 22 h, the cells 
were washed, trypsinized and centrifuged. Appropriate gating was applied by means 
of the scatterplot of untreated cells to select for intact cells. Then the cells were 
resuspended in flow buffer and the average GFP expression of the total gated 
population of cells and the amount of GFP-positive cells in the same gate were 
subsequently measured by FACS Calibur flow cytometer (Beckton Dickinson, 
Erembodegem, Belgium). The analyses were done by using Cellquest software 
(Beckton Dickinson, Erembodegem, Belgium). 
4.5.3  Cell viability  
In order to analyze the cytotoxicity related to the application of different polymers 
with different Mw’s and mass ratios, viability measurements were performed. Cell 
viability measurements determine healthy cells in a sample. This can be 
accomplished either by directly counting the number of living cells or by measuring 
an indicator related to the amount of living cells in cell populations. An increase in 
cell viability shows cell proliferation, while a decrease in viability may be the result 
of either toxic effects of the particular polymer or inappropriate culture conditions 
(Roche, 2003).take and transfection efficiency studies. 
4.5.3.1 MTT assay  
Most viability assays are based on one of two characteristic parameters, namely 
metabolic activity or cell membrane integrity of healthy cells. In this study, the 
metabolic activity was measured in cell populations by incubating the cells with a 
product, called MTT reagent. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reagent is  a yellow colored tetrazolium salt, that is 
reduced into a purple colored product, which is formazan, by metabolically active 
cells. 
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Figure 4.12 : Reduction of MTT reagent to formazan. 
This colorimetric test also gives the possibility to see the color change and viability 
of cells visually. More dense purple color indicates more MTT reagents that is 
reduced to formazan which means more living cells. Finally, the analyses were 
quantified by measurement of  the absorbance by Micro Plate Reader. 
4.5.3.2 Experimental  
The cells were seeded into 96-well plates with a confluence of 1,0 x 10
4
 cells/well 
(0,25x10
4 
cells per cm
2
) and allowed to adhere overnight. The next day, freshly 
prepared polyplexes, including 0,2 µg of plasmid/well, were added to the cells. The 
concentration of  pDNA was proportional to the amount of cells, thus the same 
concentration was used as uptake and transfection experiments. Then, the same 
procedure as transfection studies was applied. 24 h after the addition of polyplexes, 
the old CCM was removed with fresh CCM  and 10 µL MTT labeling reagent was 
added per well. After 4 h incubation, 100 µL (x10 of first reagent) of solubilizing 
reagent was added incubated overnight. As a negative control, some wells were only 
treated with MTT reagents. Next, the cell viability was analyzed by measuring the 
absorbance at 590 nm with a reference at 690 nm by a Micro Plate Reader. 
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5.  RESULTS AND DISCUSSIONS 
5.1 Polymer Synthesis 
5.1.1 Characterization of polymers 
5.1.1.1 pDMAEMA 
Characterization of pDMAEMA polymer was performed at the end of purification 
and lyophilization steps. The 
1
H-NMR (300 MHz) spectrum of pDMAEMA was 
recorded in CDCl3 solvent after the radical polymerization with AIBN initiator. The 
measurement was applied relative to tetramethylsilane (TMS) at 25⁰C. 
The absence of sharp monomer peaks at 5.5 ppm and 6 ppm (See Figure 5.1) which 
represent the double bonds verifies the purity of the polymer. As these peaks are not 
observed in the spectrum of synthesized pDMAEMA (See Figure 5.2), it can be 
concluded that complete conversion of DMAEMA monomer to pDMAEMA 
polymer took place or that unreacted monomers were removed during the 
purification process. 
5.1.1.2 SS-PAAs 
Three different types of linear, disulfide linkage containing PAAs were synthesized 
via Michael type polyadditon of corresponding primary amine monomers to N, N’-
cystaminebisacrylamide (CBA). The addition polymerization occurs in a stepwise 
process thus in order to obtain a polymer with highest theoretical Mw equal 
monomer ratios were used for the synthesis. Any possible toxic acrylamide end 
group residues that were not polymerized during the reaction were consumed by 
adding excess amine monomer to the reaction media in the final stage. The obtained 
polymers are easily soluble in water, alcohols and dimethyl sulfoxide, but not in 
chloroform or ether (Lin and Engbersen, 2009). The 
1
H-NMR spectrum of the HCl 
salts of the synthesized SS-PAAs in D2O were recorded on Varian Inova 
spectrometer operating at 300 MHz. 
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Figure 5.1 : Illustration of 
1
H-NMR spectrum of DMAEMA monomer. 
a 
b 
b a 
b  b a 
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Figure 5.2 : The 
1
H-NMR spectrum relative to TMS (CDCl3, 300 MHz and expressed in ppm) of pDMAEMA. The spectrum was recorded after 
radicalic polymerization of DMAEMA monomer with AIBN initiator. The corresponding H-atoms are shown on the polymer 
molecule structure. 
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As the double bond proton signals of acrylamide monomer at 5 and 7 ppm were not 
observed in 
1
H-NMR spectra of final products, the purity of synthesized polymers 
was verified (See Figure 5.3 and 5.4).
 
Figure 5.3 : The 
1
H-NMR spectrum relative to D2O (D2O, 300 MHz and expressed 
in ppm) of p(CBA-ABOL). 
 
 
Figure 5.4: The 
1
H-NMR spectrum relative to D2O (D2O, 300 MHz and expressed in  
ppm) of p(CBA-HIS). 
Gel Permeation Chromatography (GPC) measurements were performed using a 
Waters 2695 LC system and two thermostated (30°C) PL aquagel-OH 30 columns (8 
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μm, 300×7.5mm, with a low-molar-mass separation range (200 ~ 40,000)) as 
previously described by Lin et. al. (2007a). Data were collected using a differential 
refractometer (Model 2414). 0.3 M NaAc aqueous solution (pH 4.4) plus methanol 
(70/30, v/v) was used as eluent at a flow rate of 0.5 mL/min. The GPC 
chromatograms (GPC) showed that the weight-average molecular weight (Mw) of 
p(CBA-ABOL) was 5.24 kDa and p(CBA-HIS) 7.48 kDa, with polydispersity 
indexes (pDI) 1.29 and 1.66, respectively (See Figure 5.5 and 5.6). 
 
Figure 5.5: Illustration of the Mw distribution of p(CBA-ABOL) obtained by gel 
permeation chromatography. 
 
           Figure 5.6: Illustration of the Mw distribution of p(CBA-HIS) obtained by gel 
permeation chromatography. 
Additionally the buffering capacity and polymer degradation studies were previously 
performed by Lin et. al. (2007a). The buffer capacity of the SS-PAA polymers, 
defined as the percentage of amine groups that becomes protonated when pH 
decreases from 7.4 to 5.1 (i.e., the pH change from the extracellular environment to 
p(CBA-HIS) 
p(CBA-ABOL) 
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the lower pH of the endosomes), was measured by acid-base titration. A known 
amount of polymer which was isolated as its HCl-salt form was dissolved and titrated 
by 0.1 M NaCl. p(CBA-ABOL) that is a polymer lacking a proton-acceptor side 
group shows good buffer capacity of 72% whereas, p(CBA-HIS) with imidazole side 
chain has a buffer capacity of 58%. These values are reported to be significantly 
higher than that of PEI (24%). The hydrolytic and reductive degradation profile of 
SS-PAAs was analyzed by GPC in the absence and presence of reduction agent 
dithiothreitol (DTT, 2.5 mM), mimicking the physiological and intracellular 
environment, respectively. The analyses indicated that SS-PAAs were reduced very 
slowly in the absence of DTT however, in the reductive environment with DTT a 
rapid degradation of polymers within 5 min. was reported. 
5.2 pDMAEMA Polyplexes  
Since naked DNA is not capable of passing the cellular membrane efficiently, a 
carrier system is needed for gene delivery purposes (Behr, 1993). Cationic polymers 
were widely investigated as safe carrier systems. As a promising candidate of 
cationic polymer vectors, pDMAEMA was evaluated in terms of its physicochemical 
characteristics and biological efficiency on ARPE-19 cells. 
5.2.1 Physicochemical characterization 
Stability in the extracellular environment is the first necessary condition for an 
efficient vector system. The size and surface charge of pDMAEMA/pDNA 
complexes were characterized by DLS. The influence of Mw and different 
polymer/pDNA (w/w) ratios on the polyplex stability was investigated this way. 
Moreover, agarose gel electrophoresis was applied to analyze the pDNA 
condensation ability of pDMAEMA. 
5.2.1.1 Particle size and surface charge measurements  
Prior to the in vitro evaluation of the pDMAEMA polymer, the complex stability 
characteristics such as particle size, pDI and surface charge of pDMAEMA/pDNA 
complexes were analyzed. The amounts of polymer and plasmid that are used to 
prepare the polyplexes are given in Table 5.1. 
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It can be seen from Table 5.2 that the average particle size of all polyplexes are in the 
range 100-150 nm. The increase in the Mw does not have an indicative effect on 
charge and pDI of the polyplexes (See Figure 5.7). However, as the polymer/pDNA 
ratio increases particles get smaller. It is observed that in OptiMEM, polyplexes with 
higher polymer/pDNA ratio are more densely condensed than the polyplexes with a 
lower amount of polymer. 
   Table 5.1 : The amounts of pDMAEMA polymer and pDNA which was used to 
obtained desired polymer/pDNA (w/w) ratios. 
p
D
M
A
E
M
A
 
Polymer Mw mass ratio mpolymer (μg)  mpDNA (μg) 
50 kDa 
1.5/1 15 10 
12/1 120 10 
600 kDa 
1.5/1 15 10 
12/1 120 10 
   Table 5.2 : Illustration of average size, pDI and charge values for pDMAEMA 
polyplexes. 
pDMAEMA pplx HEPES OptiMEM 
Mw mass ratio size (nm) pDI 
Ζ-potential 
(mV) size (nm) pDI 
50 kDa 
1.5/1 140,9 0,35 30,4 323,9 0,21 
12/1 103,3 0,32 31,8 104,1 0,2 
600 kDa 
1.5/1 146,4 0,16 24,9 432,5 0,19 
12/1 110,8 0,37 31,2 120,8 0,22 
5.2.1.2 pDNA complexation efficiency  
The influence of both Mw and mass ratio of pDMAEMA on pDNA condensation 
and polyplex formation ability was analyzed by agarose gel electrophoresis, the 
results of which are presented in Figure 5.8. Lane number 3,4,5 and 6 indicate the 
different polyplexes prepared in HEPES buffer (25 mM, pH 7.2). The following four 
lanes, numbers 7,8,9 and 10, are loaded with the same polyplexes which are diluted 
in OptiMEM after polyplex formation. Finally, the last four lanes show the 
polyplexes prepared in HEPES buffer, to which 20 μL heparin solution (7 μg/μL) 
was added. The Et-Br signals are localized in the wells, indicating that all the 
complexes condense the pDNA efficiently. Surprisingly, pDNA displacement by 
heparin did not yield a similar signal as observed in lane 2, yet it was still different 
from the normal complexed pDNA in the former 8 lanes. 
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     Figure 5.7 : Illustration of a. particle size and polydispersity, b. ζ-potential of 
pDMAEMA polyplexes with different Mw and mass ratios.  
 
 
 
   a. 
b. 
 
 
 
The charts give the output of DLS analyses. The results are average of 3 
measurements and shown with standard deviations. For size and pDI measurements 
complexes were prepared both in HEPES buffer solution (25 mM, pH 7.2) and 
OptiMEM serum free transfection medium. Since OptiMEM media is rich in different 
types of proteins and dissolved ions, charge measurements were only carried out with 
the polyplexes that are prepared in HEPES. In Figure a., the primary y-axis shows the 
Z-averaged size in nm and secondary y-axis shows the corresponding pDI. The x-axis 
indicates the polymer type, the polymer/pDNa (w/w) ratio and Mw of the polymer 
used. It can be seen in figure a. only influence of polymer ratio is that a lower ratio 
gives rise to large particles in OptiMEM, possibly aggregates. Figure b. shows the zeta 
potential measurements in HEPES media, which appear more or less constant around 
+30 mV for all ratios and MW’s. 
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.   
Figure 5.8 : Agarose gel electrophoresis of pDMAEMA polyplexes Mw 50 kDa and 
600 kDa with different mass ratios. The lanes with the polyplexes 
contain 20 µL of sample (corresponding to 200 ng of pDNA per well). 
As a negative control, 20 µL of heparin (7 μg/μL) was added to last 4 
samples to simulate pDNA displacement. 
5.2.2 In vitro biological evaluation  
The ability of the polymer to form stable complexes and condense the pDNA 
efficiently is the first key for an efficient cellular uptake and transfection. Following 
the complex characterization measurements, in vitro biological evaluations of the 
polyplexes both with different Mw and polymer mass ratios, in terms of uptake and 
transfection efficiency and cell viability were investigated. 
5.2.2.1 Uptake efficiency  
The uptake efficiency of stable pDMAEMA/pDNA complexes was analyzed by flow 
cytometry. The negative control samples of both untreated cells and the cells at 4⁰C 
did not show any cellular uptake more than the autofluoresence of the cells, as 
expected. Because as it is known, at 4⁰C the metabolic activity of cells slows down 
as well as the uptake. Figure 5.9 shows the uptake efficiency results of pDMAEMA 
polyplexes based on two different Mw and mass ratios with their negative controls. It 
can be seen from figure that the percentage of positive cells is higher for the cells 
treated with 12/1 polyplexes, indicating a more efficient uptake. Moreover, the effect 
of Mw is clear for the complexes with 1.5/1 mass ratio. The increment in the Mw for 
the same polymer/pDNA ratio shows 3 times increase for the uptake efficiency. 
 
 
 1    2    3    4    5    6    7   8    9   10  11  12  13 14 
1. Ladder (1kb) 
2. Pure pGL4.13 plasmid  
3. 50 kDa 1.5/1 in HEPES 
4. 50 kDa 12/1 in HEPES 
5. 600 kDa 1.5/1 in HEPES 
6. 600 kDa 12/1 in HEPES 
7. 50 kDa 1.5/1 in OptiMEM  
8. 50 kDa 12 in OptiMEM  
9. 600 kDa 1.5 in OptiMEM  
10. 600 kDa 12 in OptiMEM  
11. 50 kDa 1.5 + 20 µL Heparin  
12. 50 kDa 12 + 20 µL Heparin  
13. 600 kDa 1.5 + 20 µL Heparin  
14. 600 kDa 12 + 20 µL Heparin  
 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Figure 5.9 : Comparison of cellular internalization of p(DMAEMA) polyplexes 
with different Mw and mass ratios. 
5.2.2.2 Transfection efficiency  
The influence of pDMAEMA Mw and polymer mass ratio on transfection efficiency 
of ARPE-19 cells was determined by flow cytometry. The samples were analyzed 24 
h after the addition of polyplexes. % positive GFP expression of polyplex samples 
and their controls is shown in Figure 5.10. Similar to uptake negative control, no 
transfection was observed for cells and the negative control for transfection. The 
positive control, LF transfected nearly 50% of the cells. The pDMAEMA complexes 
with lower polymer amount almost did not transfect the cells. On the other hand, the 
polyplexes with 12/1 ratio showed very low transfection efficiency. 
5.2.2.3 Cell viability 
The cytotoxic effect of pDMAEMA polyplexes on ARPE-19 cell viability was 
analyzed with MTT assay by means of absorbance measurement of formazan dye 
that comes from the reduced MTT by metabolically active cells. 
 
 
 
p(DMAEMA) polyplexes with fluorescently labeled pGL4.13 plasmid (2 μg pDNA per 
well) were added to the cells the next day of the seeding. After 2 hours, extracellular 
fluorescence, which is emitted by the polyplexes that are attached to the cell, but not 
taken up, was quenched with 0.2 % trypan blue solution. As a negative control for uptake, 
one set of the same polyplexes were put at 4⁰C. Flow cytometry was used to analyze the 
uptake efficiency of ARPE-19 cells by the means of the mean YOYO-1 fluorescence 
(green bars) and blue bars represent the % uptake positive cells. The data are shown with 
standard deviation of three independent samples. 
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Figure 5.10 : Comparison of transfection efficiency of pDMAEMA polyplexes with   
different Mw and mass ratios and LF as a positive control.  
In Figure 5.11, it can be seen that adding more polymer to the cells resulted in a 
significant decrease of metabolic cell activity, which can indicate higher cytotoxicity. 
The effect of polymer Mw on toxicity of polyplexes is less clear in case of 1.5/1 ratio 
as both Mws show relatively moderate viability of cells.  
5.2.3 Discussion 
In this part of the study, pDMAEMA homopolymers were synthesized and evaluated 
as a candidate to be a gene delivery vector. Since the stability in the extracellular 
environment is the primary condition for an efficient carrier, the size and surface 
charge of pDMAEMA/pDNA complexes were characterized by DLS in both HEPES 
buffer and OptiMEM, the latter being representative for physiological conditions. 
 
 
 
Data shown here represents average values of 3 independent measurements, where the 
errors bars denote the standard deviation between these measurements. The next day of 
the seeding, cells were transfected with polyplexes that are prepared with gWiz™-GFP 
plasmid which encodes a gene that translates into green fluorescence protein (GFP) 
(containing 2 μg pDNA per well). Hence, this protein emits green fluorescence under the 
right excitation light. The gating, which is the selection of the appropriate cells based on 
their size and granularity, was applied by adjusting the FSC and SSC. After 24 h the 
amount of GFP-positive cells (purple bars) and the mean average GFP expression of 
the total gated population of cells  (pink bars) were measured by flow cytometry. Non-
treated cells and the cells which were transfected with non-fluorescent pGL4.13 plasmid 
were negative controls for transfection experiments. 
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     Figure 5.11 : Cell viability results of pDMAEMA polyplexes with different Mw 
and polymer ratios. 
The difference in Mw for the same polymer/pDNA (w/w) ratios did not show a 
significant effect on the polyplex stability (See Figure 5.7). This was not surprising 
because the charge density per weight would be the same both for 50 kDa and 600 
kDa polymer. Hence the amount of positive charges of polymer that will bind the 
negative charge of pDNA and form complexes does not change in both cases. 
However, the increase in polymer/pDNA ratio resulted in smaller particles that could 
be because  more positive charges lead to stronger complexation. For the complexes 
with lower polymer mass ratio in OptiMEM, the interactions between proteins and 
polyplexes may cause an increase in particle size, resulting in more stable complexes 
than the ones in HEPES buffer. Secondly, agarose gel electrophoresis was applied to 
analyze the pDNA condensation ability of polyplexes as shown in Figure 5.8. It was 
reported by Arscott et al. that DNA condensation occurs when 90% of the anionic 
charges of pDNA is condensed by the positive charges of the polymer (1990). All the 
samples showed a great ability to form stable complexes and condense the pDNA 
 
The results are shown with standard deviations of 5 independent samples. The cells 
were seeded on transparent 96-well plates at 1x10
4
 cells per well. The wells were 
treated in the same way with transfection studies but with a pDNA concentration of 0,2 
µg per well (see section 4.5). As a negative control, the cells only with MTT reagents 
were applied. LF/pDNA complexes were prepared as positive control. After 3 days, the 
absorbance was measured by Microplate Reader. The influence of higher polymer 
ratios on cell viability can be significantly observed. (°) normalized against cells which 
were not incubated with polyplexes. (*) indicates significant differences with p< 0.05 
in comparison to LF (ANOVA). 
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efficiently, even the 1.5/1 polyplexes with lowest polymer/pDNA mass ratio. 
Heparin was added to the complexes as a negative control to simulate the pDNA 
displacement. The effect of heparin did not displace the pDNA completely as 
expected, which could be due to the plasmid still being bound to smaller fractions of 
polymer. Nevertheless, even if the complete pDNA displacement effect of heparin 
cannot observed, it should be emphasized that when it is compared with the polyplex 
samples that were not treated with heparin, no pDNA displacement was seen for 
them. 
The physicochemical characteristics of pDMAEMA polyplexes were verified with 
the satisfying results of stable complexes and efficiency for pDNA complexation. 
Afterwards, the cellular processing of the pDMAEMA/pDNA complexes on ARPE-
19 cells was performed. In terms of biological evaluation of pDMAEMA polymers 
the uptake and transfection efficiency of polyplexes were investigated by flow 
cytometry and then cell viability was analyzed by an MTT assay. The MTT assay 
measures metabolic activity by the increase of absorbance by formazan crystals that 
are reduced. pDMAEMA/pDNA complexes with higher Mw and higher 
polymer/pDNA ratio showed promising results for cellular uptake (See Figure 5.9). 
They were taken up by the cells with a maximum of 70%. The influence of polymer 
amount on pDMAEMA uptake efficiency was previously explained by van de 
Wetering et al. that the amount of free polymer would increase as the polymer ratio 
in the polyplex increases which results in higher membrane destabilization thereby 
facilitating the cellular uptake of polyplexes (1997). Moreover, the increment in the 
Mw for the same polymer/pDNA ratio showed 3 times increase for the uptake 
efficiency. It was also stated that higher Mw polymers form smaller particles because 
they can condense the pDNA more strongly. Thus polyplexes can permeate through 
the membrane easily and this results relatively increased uptake and number of 
transfected cells (van de Wetering et al, 1997). However, the fact that this effect did 
not observed for cellular uptake of the polyplexes with 12/1 mass ratio with 600 kDa 
polymer could be explained by the maximization of uptake around 80% for 
pDMAEMA polyplexes. 
Following the cellular entry by means of endosomal vesicles, another key is the 
escape from endosomes prior to the transport to the nucleus. The pDMAEMA 
homopolymer has tertiary amine groups which are partially protonated at 
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physiological pH and therefore can be further protonated at endosomal pH. As it was 
indicated by van de Wetering et.al, pDMAEMA shows an average pKa value of 7.5 
where 50% of the amino groups in the polymer chain are protonated (1999). This 
answers the requirement for endosomal escape for methacrylate based polymers 
according to the proton sponge hypothesis (Dubruel et al, 2003). However, the 
transfection efficiency of pDMAEMA was very limited. The polyplexes both with 
the ratio of 1.5/1 and 12/1 showed almost no transfection for ARPE-19 cells. This 
fact was previously explained by Jones et. al. that although, pDMAEMA disrupts the 
endosomes when internalized by the endosomal vesicles, it does not induce the 
release of therapeutic material into the cytosol (2004). This could be because of the 
strong DNA binding ability of the polymer that does not allow the plasmid to be 
released once it reaches the cytosol or there may be another factor that limits the 
disassembly of the complexes to be released in the cytosol. 
Subsequently, when the cell viability was evaluated by MTT assay, it was also 
observed that higher polymer ratio gave rise to higher cytotoxic effect on ARPE-19 
cells in vitro. Since many cationic polymers, including pDMAEMA, were reported to 
have higher cytotoxicity (Layman et al, 2009), the investigation of an alternative 
delivery system with higher transfection efficiency and less cytotoxic effects was 
necessary. 
5.3 SS-PAA Polyplexes 
Cationic polymers have been attractive research materials as non-viral gene delivery 
vectors due to their lack of specific immune response, large scale DNA loading 
capacity and ease of production (Pack et al, 2005). Besides numerous types of 
cationic polymers which are investigated as gene carriers, poly(amidoamine)s 
(PAAs) are a unique family of cationic polymer therapeutics. They are reported to 
have a good solubility in water, be hydrolytically more stable and biodegradable 
(Ferruti et al, 2002).  Recently, a new series of linear PAAs containing repetitive 
disulfide linkages in their main chain has been developed by the Engbersen Lab. (Lin 
et. al, 2007a). The disulfide linkage present in SS-PAAs, which are relatively stable 
in extracellular environment, provides bioreducibility in the intracellular media.  
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In this project, physicochemical and biological properties of SS-PAAs with different 
polymer/pDNA (w/w) ratios, variable coating strategies and buffering capacity were 
evaluated. 
5.3.1 p(CBA-ABOL) polyplexes  
p(CBA-ABOL) is one of the examples of SS-PAAs as a potential gene delivery 
vector. It was obtained by Michael type polyaddition of 4-amino-1-butanol (ABOL) 
to N,N’-cystaminebisacrylamide (CBA). The ABOL-side group provides the positive 
charge and buffering capacity, while the repetitive disulfide linkage present in its 
main chain makes the polymer bioreducible and a good candidate for gene delivery 
applications. 
5.3.1.1 Physicochemical characterization  
Particle size and surface charge measurements 
The particle size and surface charge measurements of p(CBA-ABOL) polyplexes 
with various polymer/pDNA mass ratios were determined by DLS, in order to have 
an idea about the stability range of the p(CBA-ABOL) polyplexes. The amount of 
polymer and pDNA which was used while preparing the complexes is illustrated on 
Table 5.3 and the measurement values can be found on Table 5.4. As  it is shown in 
Figure 5.12 a, the complexes in HEPES indicates a narrow size range between 120-
150 nm with a stable pDI value. Polyplexes with the ratio of 96/1 has the most 
positive surface charge with +45.53 mV. However, in  OptiMEM media the 
increasing amount of polymer resulted in very large aggregates. 
Table 5.3: The amounts of p(CBA-ABOL) polymer and pDNA which was used to 
obtain desired polymer/pDNA (w/w) ratios. The polyplexes were 
prepared with increasing amount of polymer while the amount of plasmid 
was the same for each. 
mass ratio m polymer (μg) m pDNA (μg) 
12/1 120 10 
 24/1 240 10 
 48/1 480 10 
  96/1  960 10 
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    Table 5.4 : Illustration of size, pDI and charge values for p(CBA-ABOL) pplxes 
with different polymer/pDNA mass ratios. 
p
(C
B
A
-A
B
O
L
) 
mass ratio 
HEPES OptiMEM 
size (nm) pDI 
Z-potential 
(mV) size (nm) pDI 
12/1 147,93 0,1 27,57 449,70 0,14 
 24/1 134,27 0,11 29,83 511,00 0,20 
 48/1 122,47 0,11 43,1 744,00 0,37 
96/1  132,17 0,07 45,53 1335,00 0,62 
pDNA complexation efficiency 
The relation between the amount polymer and DNA condensation ability while 
forming stable complexes were analyzed by agarose gel electrophoresis. Polyplexes 
which were prepared in HEPES buffer with increasing mass ratio of p(CBA-ABOL) 
were loaded into lanes number 3,4,5 and 6, respectively (See Figure 5.13). It can be 
seen from the figure that the free DNA bands become less clear above a 
polymer/pDNA mass ratio of 12/1. This indicates that increasing polymer ratios form 
complexes with increased pDNA complexation efficiency. The following four lanes, 
number 7,8,9 and 10, were loaded with the same polyplexes which were diluted in 
OptiMEM after polyplex formation in HEPES buffer. The bands of the pDNA that 
migrated from the polyplexes in OptiMEM become more visible which corresponds 
to more pDNA release.  
 
      Figure 5.12 : Illustration of  a. particle size and polydispersity, b. ζ-potential of 
p(CBA-ABOL) polyplexes with different mass ratios. 
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Figure 5.12 (continued) : Illustration of  a. particle size and polydispersity, b. ζ-      
potential of p(CBA-ABOL) polyplexes with different mass 
ratios. 
When it is compared with lane numbers 7,8,9 and 10, it can be concluded that the 
release in OptiMEM is not negligible but there is still some plasmid left in the wells. 
The pDNA binding ability of the polyplexes with 48/1 ratio supports the stable 
results which were obtained from DLS, as well. 
  
Figure 5.13 : Agarose gel electrophoresis of p(CBA-ABOL) pplxes with different 
mass ratios. Each sample was colored with 5 µL loading buffer. The 
polyplex samples contain 0.2 µg of pDNA. As a negative control, 10 
µL of Heparin (7 μg/μL) was added to last sample. 
1. Ladder (1 kb) 
2. Pure pGL4.13 plasmid 
3. Pplx 12/1 in HEPES 
4. Pplx 24/1 in HEPES 
5. Pplx 48/1 in HEPES 
6. Pplx 96/1 in HEPES 
7. Pplx 12/1 in OptiMEM 
8. Pplx 24/1 in OptiMEM 
9. Pplx 48/1 in OptiMEM 
10. Pplx 96/1 in OptiMEM 
11. Pplx 48/1 + 10 µl Heparin 
  1     2    3     4     5     6     7      8     9    10   11   
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5.3.1.2 In vitro biological evaluation  
After the physicochemical characterization of p(CBA-ABOL) polyplexes, the effect 
of polymer/pDNA ratio on biological evaluation of the polyplexes in terms of uptake 
and transfection efficiency and cell viability was analyzed. 
Uptake efficiency  
In order to determine effect of mass ratio on the uptake efficiency of p(CBA-ABOL) 
polyplexes, ARPE-19 cells were incubated with polyplexes and analyzed by flow 
cytometry (Figure 5.14). It can be seen from the figure that for the samples at 37⁰C, 
an increasing amount of polymer results in a higher uptake efficiency. The uptake 
efficiency of 96/1 ratio reaches to 90% whereas it results in 10% for 12/1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 : Comparison of cellular internalization of p(CBA-ABOL) polyplexes 
with different mass ratios. 
 
 
 
The data are shown with standard deviation of three independent samples. p(CBA-
ABOL) polyplexes with fluorescently labeled pGL4.13 plasmid (2 μg pDNA per well) 
were added to the cells the next day of the seeding. After 2 hours, extracellular 
fluorescence, which is emitted by the polyplexes that are attached to the cell, but not 
taken up, was quenched with 0.2 % trypan blue solution.As a negative control for 
uptake, one set of the same polyplexes were put at 4⁰C. Flow cytometry was used to 
analyze the uptake efficiency of ARPE-19 cells by the means of the mean YOYO-1 
fluorescence (green bars) and blue bars represent the % uptake positive cells. 
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Transfection efficiency  
p(CBA-ABOL) polyplexes with different polymer/pDNA (w/w) ratio were evaluated 
in terms of GFP expression on ARPE-19 cells. Figure 5.15 shows the transfection 
efficiencies of polyplex samples and their negative controls analyzed by flow 
cytometry. The negative control samples which were prepared with non-fluorescent 
pGL4.13 plasmid and cells showed no transfection, not more than auto-fluorescence. 
The polyplexes with 12/1 ratio indicate very low transfection efficiency while the 
complexes with higher polymer ratios show about 30% transfection efficiency. The 
GFP expression of 96/1 ratio reaches to 40%. Whereas, the transfection efficiency of 
positive control samples with LF that is commercially available and known to have 
good transfection, reaches to 30 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 : Comparison of transfection efficiencies of p(CBA-ABOL) polyplexes 
with various mass ratios compared to LF.  
 
 
 
The experiments were carried out in triplicate and data are shown with standard 
deviation. The day after the seeding, the cells were transfected with p(CBA-ABOL) 
polyplexes prepared with gWiz™-GFP plasmid (2 µg pDNA concentration per well). 
Then the mean average GFP expression of the total gated population of cells (pink 
bars) and the amount of GFP-positive cells (purple bars) were measured by flow 
cytometry. Non-treated cells and the cells which were transfected with non-fluorescent 
pGL4.13 plasmid were negative controls for transfection experiments. 
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Cell viability 
The cytotoxic effects of p(CBA-ABOL) complexes with different polymer mass 
ratios (w/w) were analyzed by means of the MTT assay. The cells were incubated 
with the same polymer/pDNA ratios as was used for the transfection experiments. 
However, the amount of sample which was added to the cells was proportional to the 
cell confluence. The cell viability percentage of ARPE-19 cells which were treated 
with p(CBA-ABOL) complexes is shown in Figure 5.16. The 48/1 ratio was seen to 
have the lowest cytotoxic effect on the cells, equal to that of LF. The increase in the 
amount of polymer for 96/1 ratio resulted in more toxicity and less viability for 
ARPE-19 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 5.16 :  Cell viability results of p(CBA-ABOL)/pDNA polyplexes with 
different mass ratios. 
5.3.1.3 Discussion 
In the first part of this study pDMAEMA polyplexes were evaluated as potential 
gene delivery vectors. Even though pDMAEMA formed stable complexes with 
 
The cells were treated in the same way with transfection studies but with a pDNA 
concentration of 0,2 µg per well. As a negative control, only MTT reagents were added 
to the cells. LF/pDNA complexes were prepared as positive control. The third day, the 
absorbance was measured by Microplate Reader at 590 nm. The results are shown with 
standard deviations of 5 independent samples. (°) normalized against cells which were 
not incubated with polyplexes. (*) indicates significant differences with p< 0.05 in 
comparison to LF (ANOVA). 
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pDNA, it could only transfect the cells somewhat at polymer/pDNA ratios which 
were toxic to the cells. As SS-PAAs were reported to be efficient  p(CBA-ABOL) 
was chosen to be evaluated as a promising member of this family. The repetitive 
disulfide linkages present in the CBA monomer chain makes the polymer 
bioreducible, whereas hydroxybutyl groups in the side chain originating from the 
ABOL unit enrich the efficiency in DNA transfection by increasing the 
endosomolytic properties of polyplexes (Lin et. al, 2007a). 
In this section, prior to biological evaluation of p(CBA-ABOL), the polymer/pDNA 
complexes were physicochemically characterized. The ability of the polymer to form 
stable complexes with DNA and the influence of polymer/pDNA (w/w) ratios on 
colloidal stability of complexes were analyzed by DLS. The size, polydispersity and 
surface charge measurements of p(CBA-ABOL) polyplexes showed  that the 
increase in the amount of polymer resulted in more stable and more positive 
complexes in HEPES buffer.. Hence, all polyplexes with 4 different mass ratios 
(12/1, 24/1, 48/1 and 96/1) were capable to form nanosized polyelectrolyte 
complexes by the means of self assembly in HEPES buffer. The same measurements 
were also performed in OptiMEM to simulate physiological conditions. However, 
due to the the interactions of proteins and various ions that are present in OptiMEM, 
polyplex particles caused very large aggregates as the polymer amount increases. 
According to agarose gel electrophoresis results, all p(CBA-ABOL) polyplexes were 
able to condense the pDNA but the ones with 48/1 and 96/1 polymer/pDNA ratio 
were more efficient in terms of DNA binding (See Figure 5.13). As the amount of 
polymer increases corresponding to the same amount of pDNA, when the pDNA is 
condensed with the cationic polymer at some point, this could be that free polymer 
causes the increment in surface charge and pDNA binding ability. 
To further evaluate the effect of polymer/pDNA (w/w) ratio on biological efficiency 
of p(CBA-ABOL) polyplexes the same 4 ratios were used for uptake and transfection 
efficiency experiments as well as for MTT assay. The uptake efficiency results, 
which were determined by flow cytometry, clearly indicated that increasing amount 
of polymer resulted in higher percentages of cellular uptake (See Figure 5.14). When 
it is compared with pDMAEMA, p(CBA-ABOL) polyplexes have higher uptake that 
is probably due to more positive charges present in the polyplexes with higher 
amount of polymer. This effect could be facilitated the interactions between anionic 
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cell membrane HSPGs. Especially the ratios 48/1 and 96/1 were observed to be more 
efficient in terms of uptake. After the cellular entry via endocytosis, the escape from 
endosomes and the release of the pDNA from polymer are the requirements for gene 
expression. The p(CBA-ABOL) polyplexes showed highly efficient transfection 
relative to LF, which was used as a positive control, by increasing amount of 
polymer. If it is compared with previous carrier system pDMAEMA, we assume the 
effect of hydrophobic side chain such as ABOL and rapid release of pDNA following 
the endosomal escape by the means of disulfide cleavage in the intracellular 
reductive environment give rise to higher pDNA transfection and increased level of 
gene expression (Lin and Engbersen, 2009). Cell viability of p(CBA-ABOL) 
polyplexes with different mass ratios which was analyzed by MTT assay showed that 
p(CBA-ABOL)/pDNA complexes possess very low cytotoxicity on ARPE-19 cells 
relative to LF especially compared to pDMAEMA. Nevertheless, 96/1 ratio with the 
maximum transfection efficiency showed significantly lower viability on ARPE-19 
cells. 
In conclusion, p(CBA-ABOL) was determined as a good non-viral carrier.  As the 
pDMAEMA polymer, it was able to form stable polyplexes, yet it also showed high 
cellular uptake and transfection efficiency results with very low cytotoxicity. As 96/1 
ratio was stated to be relatively cytotoxic, 48/1 ratio polyplexes with similar 
physicochemical properties and biological efficiency but higher cell viability were 
chosen as a comparative reference for further experiments. Nevertheless, the 
tendency of the polyplexes to form large aggregates in physiological conditions 
dictate further optimizations for p(CBA-ABOL) to be a better vector.  
5.3.2 p(CBA-ABOL/DMEDA/PEG) polyplexes  
In order to increase the stability of gene delivery vectors in the extracellular 
environment, PEGylation is a universal strategy that is widely applied. This method 
is performed by grafting the non-ionic and hydrophilic polyethylene glycol (PEG) to 
the gene delivery vector. Since p(CBA-ABOL) polyplexes was promising non-viral 
carriers with good uptake and transfection efficiency and favorable cell viability, 
PEGylation was applied to increase their colloidal stability. In the following section, 
PEGylated particles were physicochemically and biologically evaluated. 
 
75 
5.3.2.1 Physicochemical characterization 
Particle size and surface charge measurements 
p(CBA-ABOL/DMEDA/PEG) complexes were characterized in terms of their 
particle size, surface charge and polydispersity by DLS. Complexes were prepared 
with the same amounts of polymer and pDNA of  p(CBA-ABOL) polyplexes for the 
corresponding polymer/pDNA (w/w) ratio. It can be seen from Table 5.5 that 
polyplex particles in HEPES get smaller as the amount of polymer increases. On the 
other hand, complexes have very slight positive charge even with the highest amount 
of polymer for 96/1 ratio. For the measurements in OptiMEM, it is clearly observed 
from Figure 5.17 that  polyplexes show a great stability with a size range between 
120-160 nm. 
Table 5.5 : Illustration of average size, pDI and charge values for PEGylated 
p(CBA-ABOL) polyplexes with different polymer/pDNA mass ratios. 
p
(C
B
A
-
A
B
O
L
/D
M
E
D
A
/P
E
G
) 
mass ratio 
HEPES OptiMEM 
size (nm) pDI 
Z-potential 
(mV) size (nm) pDI 
12/1 134,63 0,41 5,29 160,87 0,52 
 48/1 114,6 0,34 8,35 121,33 0,40 
96/1  108.9 0,32 9,40 152,70 0,49 
 
Figure 5.17 : Illustration of  the effect of PEGylation on a. particle size and 
polydispersity, b. ζ-potential. 
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Figure 5.17 (continued) :  Illustration of  the effect of PEGylation on a. particle size 
and polydispersity, b. ζ-potential. 
pDNA complexation efficiency 
Agarose gel electrophoresis was applied to investigate the DNA binding capability of 
PEGylated polymers. Lane numbers 3,4 and 5 indicate the polyplexes prepared in 
HEPES and number 6,7 and 8 show the complexes diluted in OptiMEM (See Figure 
5.18). It can be observed from the band intensities that PEGylated polymers have a 
more strong DNA binding ability both in HEPES and OptiMEM. Moreover, the 
polymer mass ratio above 48/1 show more stable complexes for PEGylated 
polymers. 
5.3.2.2 In vitro biological evaluation 
Uptake efficiency  
The uptake efficiency of PEGylated p(CBA-ABOL) polymer complexes with 
different polymer/pDNA (w/w) ratios on ARPE-19 cells was evaluated by flow 
cytometry. According to the results of the stability and DNA condensation ability of  
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Figure 5.18 : Agarose gel electrophoresis for p(CBA-ABOL/DMEDA/PEG) 
complexes. The lanes with the polyplexes contain 20 µL of sample 
(corresponding to 200 ng of pDNA per well). As a negative control, 5 
µL of Heparin (7 μg/μL) was added to last 3 samples to simulate pDNA 
displacement. 
the polymer, the most capable two ratios, 48/1 and 96/1, were chosen and applied for 
the uptake experiment.The non-PEGylated 48/1 p(CBA-ABOL) polyplexes were 
also applied as a comparison.  Figure 5.19 shows the efficiencies of polyplex samples 
and their negative controls. The negative control samples which were put at 4⁰C, 
showed no uptake, as expected. As expected, the cells showed positive uptake for 
p(CBA-ABOL)/pDNA complexes with 80%. However, it can be seen from Figure 
5.19 that PEGylated p(CBA-ABOL) polyplexes were almost not taken up by ARPE-
19 cells. 
Transfection efficiency  
In order to determine transfection efficiency of PEGylated p(CBA-ABOL) 
complexes ARPE-19 cells were treated with polyplexes having different mass ratios 
and the transfection efficiency was analyzed by flow cytometry. LF/pDNA 
complexes and non-PEGylated p(CBA-ABOL) polyplexes were applied as positive 
controls. As it is illustrated in Figure 5.20 that the  positive control samples showed a 
GFP expression around 25% on the other hand, PEGylated p(CBA-ABOL) 
complexes did not transfect. 
 1     2     3    4    5     6    7    8    9   10   11 
1. Ladder (1kb) 
2. Pure pGL4.13 plasmid 
3. PEG-pplx 48/1 in HEPES 
4. PEG-pplx 72/1 in HEPES 
5. PEG-pplx 96/1 in HEPES 
6. PEG-pplx 48/1 in OptiMEM 
7. PEG-pplx 72/1 in OptiMEM 
8. PEG-pplx 96/1 in OptiMEM 
9. PEG-pplx 48/1+ 5 µl Heparin  
10. PEG-pplx 72/1+ 5 µl Heparin 
11. PEG-pplx  96/1+ 5 µl Heparin 
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Figure 5.19 : The effect of  PEGylation on cellular internalization of p(CBA-ABOL) 
polyplexes with different mass ratios in ARPE-19 cells. 
 
Figure 5.20 : Comparison of the effect of PEGylation on transfection efficiency of 
p(CBA-ABOL) polyplexes with various mass ratios in ARPE-19 cells.  
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5.3.2.3 Discussion 
p(CBA-ABOL) polyplexes were evaluated as the first member of SS-PAA family in 
the previous section. p(CBA-ABOL) polymer was able to efficiently transfect the 
ARPE-19 cells, however, the complexes formed large aggregates in the extracellular 
environment. PEGylation was applied as a strategy to increase the colloidal stability 
of p(CBA-ABOL)/pDNA complexes in the extracellular environment. Synthesis of 
p(CBA-ABOL/DMEDA/PEG) was performed by Michael addition polymerization. 
p(CBA-ABOL/DMEDA) was first synthesized by the same reaction and then 
PEGylation was performed by PEG-NH2 quenching. In addition to the bioreducibility 
and DNA transfection ability of p(CBA-ABOL), N,N’-dimethylethane-1,2-diamine 
(DMEDA) group increases the positive charges present in the polymer chain which 
improves complexation and electrostatic interactions between polymer and pDNA 
(Vader et al, 2011). The effect of PEGylation on polyplex particle size and surface 
charge was characterized by DLS. It was clearly seen that PEGylated polyplexes 
form more stable complexes than unPEGylated p(CBA-ABOL) polyplexes in 
OptiMEM with a hydrodynamic diameter of 152 nm in 96/1 ratio. The surface 
charge measurements indicated less positive complexes with p(CBA-
ABOL/DMEDA/PEG) even with the highest polymer ratio of 96/1 which is because 
of PEG molecule that has a neutral surface charge in buffer conditions (Brumbach et 
al, 2010). To determine the ability of PEGylated polymer to condense the pDNA, 
agarose gel electrophoresis was applied. As it was shown in Figure 5.18, p(CBA-
ABOL/DMEDA/PEG) polyplexes were able to condense DNA in HEPES for all 
applied ratios. Additionally, the samples in OptiMEM showed less clear bands that 
represent the pDNA than p(CBA-ABOL) polyplexes which means PEGylated 
polymers can condense the pDNA more densely with the facilitating effect of 
increased polymer/pDNA mass ratio. 
In vitro biological evaluation of p(CBA-ABOL/DMEDA/PEG) polyplexes was 
analyzed by flow cytometry by the means of uptake and transfection efficiency 
which showed that these complexes showed almost no cellular uptake (See Figure 
5.19). This fact was explained by Coi (1998) and Oupicky et al. (2002) that 
PEGylation reduces the cellular association and uptake of polyplexes due to the 
steric shielding of polyplex particles. When the PEGylated particles were 
investigated for transfection efficiency on ARPE-19 cells, they did not show any 
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GFP expression where the unPEGylated p(CBA-ABOL) has transfected similar to 
positive control lipoplexes. As Lin and Engbersen stated that PEGylated poylplexes 
indicated very low transfection efficiency because their neutral surface appeases 
efficient cellular association and internalization (2009). Furthermore, the endosomal 
escape of polyplexes from acidic endosomes is also diminished by PEGylation 
(Knorr et al, 2007). Since the results of biological evaluation of PEGylated particles 
address the “PEG dilemma”, PEGylated polyplexes was not investigated in terms of 
cellular viability, because particles which are not taken up by the cell will have 
minimal influence on cell viability.  
To conclude, PEGylation of polyplexes results in reduced interaction with OptiMEM 
components giving rise to more stable particles. Nevertheless, this extracellular 
stability comes at the cost of an inefficiency for uptake and transfection observations, 
possibly due to the shielding of the surface charge, which emphasizes the need for 
alternative strategies to increase colloidal stability of p(CBA-ABOL) particles. 
5.3.3 HA-coated p(CBA-ABOL) polyplexes 
Hyaluronic acid (HA) is a cell surface GAG which is highly abundant in extracellular 
matrix (ECM). It is popularly investigated for drug delivery purposes because of 
having good biocompatibility and biodegradability (Han et al, 2009). Moreover, it 
has been reported to be responsible of cellular internalization and uptake of gene 
therapy vectors. In this section, HA-coated p(CBA-ABOL) polyplexes were 
investigated in terms of increase in the stability of complexes and in the uptake 
efficiency. 
5.3.3.1 Physicochemical characterization 
Particle size and surface charge measurements 
Particle size and surface charge measurements were carried out for a series of HA-
coated p(CBA-ABOL)/pDNA complexes with different HA/pDNA molar ratios. The 
characterization was performed by DLS. The coating was applied on p(CBA-ABOL) 
polyplex with 48/1 ratio with different amount of research grade HA that is 
purchased from Life Core Scientific. As it is shown in Figure 5.21, increasing 
amount of HA results in smaller, more negative and stable complexes in HEPES 
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buffer. The effect of increasing amount of HA is less clear for size measurements in 
OptiMEM because all the complexes have an average size of 500 nm. 
Table 5.6 : Illustration of the amount of HA and pDNA used to apply the coating in  
appropriate HA/pDNA molar ratio. 
H
A
-c
o
at
ed
  
  
  
  
  
  
  
p
(C
B
A
-A
B
O
L
) 
molar ratio  
(HA/pDNA) 
V HA 
(μL) 
m HA  
(μg) 
m pDNA 
(μg) 
25.5 /1 12.4 62 2 
63/1 30.6 153 2 
125/1 61.1 305.5 2 
190/1 92 460 2 
250/1 122.2 611 2 
313/1 153 765 2 
377/1 184 920 2 
505.5/1 244.4 1222 2 
 
Figure 5.21 : Illustration of the effect of HA-coating on a. particle size and 
polydispersity, b. ζ-potential of p(CBA-ABOL) polyplexes with 
different HA/pDNA molar ratios. 
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Figure 5.21 (continued) : Illustration of the effect of HA-coating on a. particle size 
and polydispersity, b. ζ-potential of p(CBA-ABOL) 
polyplexes with different HA/pDNA molar ratios. 
pDNA complexation efficiency 
The influence of HA-coating on the DNA condensation behavior of p(CBA-ABOL) 
complexes was observed by agarose gel electrophoresis. Based on DLS results, the 
most stable complexes were chosen and applied into gel. As a reference, non-coated 
p(CBA-ABOL) complexes with 48/1 ratio was also loaded in gel. Polyplexes which 
were prepared in HEPES buffer with increasing HA/pDNA ratio were loaded into 
lanes numbers 4,5 and 6 (See Figure 5.22). In terms of pDNA band intensity the 
complexes in HEPES, looks more or less have the same stability with non-coated 
polyplexes. Nevertheless, the slight bands of the lane numbers 8,9 and 10 that are 
loaded with HA-coated complexes in OptiMEM, clearify the effect of HA-coating on 
the stability of complexes. 
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Figure 5.22 : Agarose gel electrophoresis of HA-coated p(CBA-ABOL) polyplexes 
with different HA/pDNA mass ratios. The lanes with the polyplexes 
contain 20 µL of sample (corresponding to 200 ng of pDNA per well). 
As a negative control, 5 µL of Heparin (7 μg/μL) was added to last 4 
samples to simulate pDNA displacement. 
5.3.3.2 In vitro biological evaluation  
Uptake efficiency  
The influence of HA-coating on the uptake efficiency of stable p(CBA-ABOL) 
complexes was analyzed by flow cytometry.  A series of HA/pDNA ratios were 
applied for physicochemical characterization of HA-coated p(CBA-ABOL) 
polyplexes but only the more stable ones were chosen for the uptake experiment. 
Non-coated p(CBA-ABOL) complexes were also applied in order to compare the 
effect of HA-coating. Figure 5.23 shows the uptake efficiency results of HA-coated 
p(CBA-ABOL) polyplexes based on three different HA/pDNA molar ratios with 
their controls. The positive control samples with non-coated p(CBA-ABOL) 
polyplexes show 80% cellular uptake. The desired effect of HA-coating and 
increasing HA/pDNA ratio was not observed in terms of uptake efficiency because 
all the ratios show similar efficiency around 10% of uptake positive cells. 
Transfection efficiency  
The transfection efficiency of HA-coated p(CBA-ABOL) polyplexes with different 
HA/pDNA molar ratios was determined by flow cytometry. Polyplexes with non-
coated p(CBA-ABOL) and LF/pDNA complexes were prepared as positive controls. 
The samples were analyzed 24h after the addition of the complexes. % positive GFP 
expression of HA-coated p(CBA-ABOL) polyplex samples and their controls is 
 1    2    3    4   5   6    7   8    9   10  11 12 13 14 
1. Ladder (1kb) 
2. Pure pGL4.13 plasmid 
3. Pplx CBA-ABOL 48/1 in HEPES 
4. HA-coated 190/1 in HEPES 
5. HA-coated 313/1 in HEPES 
6. HA-coated 501,5/1 in HEPES 
7. Pplx CBA-ABOL 48/1 in OptiMEM 
8. HA-coated 190/1 in OptiMEM 
9. HA-coated 313/ in OptiMEM 
10. HA-coated 501,5/1 in OptiMEM 
11. Pplx CBA-ABOL 48/1 + 5 µL Heparin  
12. HA-coated 190/1 + 5 µL Heparin  
13. HA-coated 313/1 + 5 µL Heparin 
14. HA-coated 501,5/1 + 5 µL Heparin  
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shown in Figure 5.24. The positive control LF transfected nearly 30% of the plasmid 
while p(CBA-ABOL) had 15% GFP expression. The HA-coated polyplexes showed 
very low transfection, even with the highest HA/pDNA ratio for 400/1. 
 
Figure 5.23 : The effect of HA-coating on cellular internalization of p(CBA-ABOL) 
polyplexes with different HA/pDNA molar ratios in ARPE-19 cells. 
 
Figure 5.24 : Comparison of transfection efficiencies of different gene carriers HA-
coated p(CBA-ABOL) with different HA/pDNA molar ratios,  non-
coated p(CBA-ABOL) and LF complexes. 
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Figure 5.24 (continued) : Comparison of transfection efficiencies of different gene 
carriers HA-coated p(CBA-ABOL) with different 
HA/pDNA molar ratios,  non-coated p(CBA-ABOL) and 
LF complexes.  
Cell viability 
The effect of HA-coating for p(CBA-ABOL) polyplexes on ARPE-19 cell viability 
was analyzed with MTT Assay and the absorbance was measured by Microplate 
Reader. LF/pDNA and non-coated p(CBA-ABOL)/pDNA complexes were applied 
as positive controls. It is clearly seen on Figure 5.25 that HA-coated complexes 
indicate higher cell viability when than the positive controls. This may because of 
they are taken up with a lower efficiency with comparison to the control samples. 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 : Effect of HA-coating on the viability of ARPE-19 cells. 
 
The HA-coated p(CBA-ABOL) polyplexes with different HA/pDNA molar ratios were 
added to the cells the day after the cell seeding. The cells were treated in the same way with 
transfection studies but with a pDNA concentration of 0,2 µg per well. As a negative 
control, the cells only with MTT reagents were applied. LF/pDNA complexes were applied 
as positive control and p(CBA-ABOL) polyplexes as comparative control. The third day, 
the absorbance of cells was measured by Microplate Reader at 590 nm. No significant 
difference was observed according to statistical tests. The results are shown with standard 
deviations of 5 independent samples. (°) normalized against cells which were not incubated 
with polyplexes. (*) indicates significant differences with p< 0.05 in comparison to LF 
(ANOVA). 
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5.3.3.3 Discussion 
In the previous sections, pDMAEMA polyplexes were reported to be stable but had a 
very low transfection efficiency. Then as an alternative vector system p(CBA-
ABOL) polymer was chosen to be evaluated for its potential to be a gene delivery 
vector. p(CBA-ABOL) complexes were stable in HEPES and had promising results 
for  transfection. However, they were not stable in the extracellular environment. 
Thus PEGylation was applied to increase the stability of p(CBA-ABOL) polyplexes 
in the extracellular environment. PEGylated particles formed stable complexes in the 
extracellular media, but were not taken up and did not transfect efficiently. p(CBA-
ABOL) polyplexes should be improved in terms of stability in the extracellular 
environment and transfection efficiency. HA-coating was applied by means of 
electrostatic binding of negatively charged low molecular weight HA polymer to 
positively cored polyplexes. The choice of hyaluronan Mw was determined by the 
previous study of Hornof et. al. (2008)  and the ratio of complexes based on the 
molar ratio between HA and pDNA. By adding the HA to the polyplexes as the outer 
core of the polyplexes was coated with anionic HA, the ζ-potential of complexes 
turned negative from positive (See Figure 5.21) and resulting in a lowest value of -35 
mV. According to the Z-average diameter measurements in OptiMEM, particles with 
all ratios show a clear stability around 500 nm in average. When it is compared to 
uncoated polyplexes this drastic change in the size of particles could be because the 
polyplexes are completely restructured, perhaps with more plasmids per polyplex, 
and more polymer as well. The pDNA condensation efficiency of the polyplexes in 
OptiMEM can be seen from agarose gel electrophoresis (See Figure 5.22). The HA-
coated particles with the lowest ratio showed a slight pDNA release and the other 
two ratios were able to completely condense the pDNA which means HA-shielding 
has a positive effect on pDNA binding ability of polymer. 
For biological evaluation of HA-coated particles, uptake and transfection efficiency 
analyses were performed. In contrast to generally obtained results, the desired 
increasing effect of HA-coating could not be observed for p(CBA-ABOL) uptake 
efficiency studies. Previously, Wang et al. have reported a facilitating effect for 
cellular uptake of HA-shielded PEI/pDNA complexes (2011). 
In a preliminary study, we obtained low Mw HA with enzymatic digestion of 
hyaluronan (See App. A). The transfection efficiency results showed higher gene 
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expression than the results obtained with research grade purity HA. This could be 
due to the purity and decreased effect of HA Mw. Although we aimed low Mw by 
the enzymatic digestion, there is a possibility that the high Mw HA particles could 
not be eliminated completely by ultrafiltration. Then the mixture of low and high 
Mw HA may have resulted in increased transfection efficiency in the preliminary 
study. Moreover, the MTT assay results indicated that the cell viability is higher for 
the cells treated with HA-coated particles than uncoated particles. This could be 
because they are less toxic for the cells, but it could also be because they are not 
taken up as much as uncoated particles. Hence, the application of HA-coating should 
be further investigated. 
5.3.4 p(CBA-HIS) polyplexes 
p(CBA-HIS) was chosen to be used as a gene delivery vector due to the imidazole 
groups present in the side chain. These groups have a good buffering capacity in 
physiological conditions that is expected to be more efficient in terms of delivery of 
the plasmid to the cell nucleus. 
5.3.4.1 Physicochemical characterization 
Particle size and surface charge measurements 
The particle size and surface charge measurements of p(CBA-HIS) polyplexes with 
various polymer/pDNA mass ratio were determined by DLS. The p(CBA-
HIS)/pDNA complexes were prepared with 4 different mass ratios which were the 
same ratios that applied for p(CBA-ABOL) polyplexes. By this way, it was possible 
to compare the polyplex formation characteristics of two types of polymers. The 
amount of polymer and pDNA which was used while preparing the complexes is 
illustrated on Table 5.7 and the measurement values are given on Table 5.8. As it is 
shown in Figure 5.26, increasing amount of polymer results in smaller, more positive 
and stable complexes in HEPES buffer. However, measurements in  OptiMEM 
media indicates that the increase in  the polymer/pDNA ratio causes very large 
particles, even >1 μm for 96/1 ratio. 
 
 
88 
       Table 5.7: The amounts of p(CBA-HIS) polymer and pDNA which was used to 
obtain desired polymer/pDNA (w/w) ratios. The polyplexes were 
prepared with increasing amount of polymer while the amount of 
plasmid was constant. 
mass ratio m polymer (μg) m pDNA (μg) 
12/1 120 10 
 24/1 240 10 
 48/1 480 10 
  96/1  960 10 
       Table 5.8 : Illustration of average size, pDI and charge values for p(CBA-HIS) 
polyplexes with different polymer/pDNA mass ratios. 
p
(C
B
A
-H
IS
) mass ratio 
HEPES OptiMEM 
size (nm) pDI 
Z-potential 
(mV) size (nm) pDI 
12/1 157,07 0,08 26,87 509,70 0,05 
 24/1 117,70 0,09 31,67 598,10 0,13 
 48/1 101,80 0,10 43,70 778,97 0,22 
96/1  96,78 0,15 46,77 1036,33 0,34 
pDNA complexation efficiency 
Agarose gel electrophoresis was performed to analyze the pDNA condensation 
ability of homopolymer p(CBA-HIS)/pDNA complexes. As it is shown in the Figure 
5.27, the polyplexes were loaded into gel starting from lane number 3 and 
polymer/pDNA ratio of 12/1. 48/1 p(CBA-ABOL)/pDNA complex was also applied 
as a reference. It can be seen from the figure that above the ratio of 24/1, the bands 
become almost invisible and polymer strongly binds the pDNA. If the polyplexes 
with the same amount but different type of polymer are compared (lane number 5 
and 7), it can be concluded that p(CBA-HIS) has strong ability to condense the 
pDNA molecule. For the samples in OptiMEM, the release of pDNA is observed 
however, the bands are less bright than the ones with heparin where the pDNA was 
almost totally displaced. 
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  Figure 5.26 : Illustration of  a. particle size and polydispersity, b. ζ-potential of 
pDMAEMA polyplexes with different Mw and mass ratios. 
 
 
 
 
 
The charts give the output of DLS analyses. The results are average of 3 measurements 
and shown with standard deviations. For size and pDI measurements complexes were 
prepared both in HEPES buffer solution (25 mM, pH 7.2) and OptiMEM serum free 
transfection medium. Since OptiMEM media is rich in different types of proteins and 
dissolved ions, charge measurements were only carried out with the polyplexes that are 
prepared in HEPES. In Figure a., the primary y-axis shows the Z-averaged size in nm 
and secondary y-axis shows the corresponding pDI. The x-axis indicates the polymer 
type and the polymer/pDNa (w/w) ratio. It can be seen in figure a. that the influence of 
increasing polymer ratio gives rise to large particles in OptiMEM, possibly aggregates. 
Figure b. shows the zeta potential measurements in HEPES media, which appear to be 
maximum around +50 mV for 96/1 ratio. 
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   Figure 5.27: Agarose gel electrophoresis of p(CBA-HIS) polyplexes with different 
mass ratios. The lanes with polyplexes contain 20 µL of sample 
(corresponding to 200 ng of pDNA per well). As a negative control, 3 
µL of Heparin (7 μg/μL) was added to last 5 samples to simulate 
pDNA displacement. 48/1 p(CBA-ABOL) polyplexes were applied as 
a comparative reference. 
5.3.4.2 In vitro biological evaluation 
Uptake efficiency  
The influence of increased buffering capacity  on the uptake efficiency of ARPE-19 
cells was determined by flow cytometry (See Figure 5.28). Two mass ratios of 
p(CBA-HIS), 24/1 and 48/1, with the best physicochemical characteristics were 
chosen and applied for uptake experiment. p(CBA-ABOL) 48/1 ratio was used to 
prepare the positive control samples. Untreated cells and one set of the polyplexes 
were put at 4⁰C as negative controls. p(CBA-HIS) with 48/1 mass ratio polyplexes 
showed nearly 95% uptake which is higher than the p(CBA-ABOL) polyplexes with 
the same polymer/pDNA (w/w) ratio. 
Transfection efficiency  
Following the uptake efficiency experiment, the p(CBA-HIS) polyplexes were 
evaluated in terms of their transfection efficiency. ARPE-19 cells were treated with 
polyplexes having different mass ratios and the transfection efficiency was analyzed 
by flow cytometry. LF/pDNA complexes and p(CBA-ABOL) polyplexes were 
applied as positive controls. For positive control samples, nearly 30% GFP 
expression was observed while p(CBA-ABOL) showed a transfection efficiency 
1. Ladder (1 kbp) 
2. Pure pGL4.13 plasmid 
3.  12/1 in HEPES  
4.  24/1 in HEPES 
5.  48/1 in HEPES 
6.  96/1 in HEPES 
7. Pplx CBA-ABOL 48/1 in HEPES 
8.  12/1 in OptiMEM 
9.  24/1 in OptiMEM 
10.  48/1 in OptiMEM 
11.  96/1 in OptiMEM 
12.  12/1 + 3 µl Heparin  
13.  24/1 + 3 µl Heparin  
14.  48/1 + 3 µl Heparin  
15.  96/1 + 3 µl Heparin  
16. Pplx CBA-ABOL 48/1 + 3 µl Heparin  
1     2    3    4    5    6    7     8   9    10  11 12  13  14  15  16 
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around 10% (See Figure 5.29). On the other hand, p(CBA-HIS) complexes showed 
very low transfection for both selected polymer/pDNA ratios. 
 
Figure 5.28 : Comparison of internalization of different gene carriers p(CBA-HIS) 
with different mass ratios, p(CBA-ABOL) and LF in ARPE-19 cells. 
 
Figure 5.29 : Comparison of transfection efficiencies of different gene carriers 
p(CBA-HIS) with different mass ratios, p(CBA-ABOL) and LF in 
ARPE-19 cells. 
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Figure 5.29 (continued) : Comparison of transfection efficiencies of different gene 
carriers p(CBA-HIS) with different mass ratios, p(CBA-
ABOL) and LF in ARPE-19 cells. 
Cell viability 
The cell viability for p(CBA-HIS) polyplexes on ARPE-19 cells was analyzed with 
MTT Assay by means of absorbance measurements on Microplate Reader. LF/pDNA 
and p(CBA-ABOL)/pDNA complexes were applied as controls. It can be seen on the 
Figure 5.30 that, p(CBA-HIS)/pDNA complexes have significantly favorable cell 
viability both for 24/1 and 48/1 mass ratios. 
 
 
 
 
 
 
 
 
 
 
     Figure 5.30 : Cell viability results of p(CBA-HIS)/pDNA pplexes with different 
mass ratios. 
 
The day after the seeding, cells were treated in the same way with transfection 
studies but with a pDNA concentration of 0,2 µg per well. As a negative control, 
the cells only with MTT reagents were applied. LF/pDNA complexes were 
prepared as positive control and p(CBA-ABOL) complexes as comparative control. 
The third day, the viability of cells was determined with MTT assay. The results are 
shown with standard deviations of 5 independent samples. (°) normalized against 
cells which were not incubated with polyplexes. (*) indicates significant differences 
with p< 0.05 in comparison to LF (ANOVA). 
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5.3.4.3 Discussion 
p(CBA-HIS) is a homopolymer with imidazole side groups that was synthesized by 
Michael type polyaddition of CBA monomer with repetitive disulfide linkages to 
histamine (HIS) molecule. p(CBA-HIS) homopolymer has a buffering capacity of 
58% due to the imidazole groups (pKa ~6.5) present in the side chain (Lin et al, 
2007b). The same 4 mass ratios as p(CBA-ABOL) polyplexes were applied for both 
physicochemical and biological evaluation of p(CBA-HIS) by this way, it was 
possible to compare the effect of buffer capacity of the polymer. First of all, the 
particle size and surface charge of the polyplexes was analyzed by DLS. According 
to the data obtained by DLS for the same mass ratios, p(CBA-HIS) polyplexes 
formed smaller complexes in HEPES buffer than p(CBA-ABOL) polyplexes which 
may be because of the imidazole groups in p(CBA-HIS) giving rise to stronger 
interactions with DNA by the means of increased cationic charge (Coue and 
Engbersen, 2011). Nevertheless, the same aggregation problem in OptiMEM 
conditions was also observed for p(CBA-ABOL) polyplexes (See Figure 5.26). 
Secondly, agarose gel electrophoresis was employed to investigate the pDNA 
binding ability of p(CBA-HIS) polyplexes with various mass ratios. As it is shown in 
Figure 5.27, the DNA release bands become less clear starting from 24/1 ratio, 
indicating a stronger condensation. Moreover, p(CBA-HIS) polyplexes were able to 
condense the pDNA more efficiently in comparison to the bands of p(CBA-ABOL) 
polyplexes with the same mass ratio of 48/1.  
The uptake and transfection efficiency of p(CBA-HIS) polyplexes on ARPE-19 cells 
was studied with 2 stable mass ratios of  24/1 and 48/1. Furthermore, cell viability of 
ARPE-19 cells that are incubated with p(CBA-HIS) polyplexes was analyzed by 
MTT assay. The uptake efficiency results clearly showed that, p(CBA-HIS) 
polyplexes are taken up with a higher percentage. Especially at 48/1 polymer/pDNA 
mass ratios where pDNA is condensed into smaller and more positively-charged 
nanoparticles, the cellular uptake is much increased with comparison to p(CBA-
ABOL) polyplexes. The transfection efficiency results of p(CBA-HIS) polyplexes 
were quite unexpected. The pKa of imidazole groups present in histamine side chains 
is in the range of endosomal acidification (pH 7.4–5.1) (Coue and Engbersen, 2011). 
By this way, these polyplexes were supposed have an advantage of extra pH-
responsiveness during endosomal escape which would result in higher transfection 
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efficiency. However, as it is illustrated in Figure 5.29 that p(CBA-HIS) polyplexes 
have very low GFP expression where the LF control and p(CBA-ABOL) complexes 
show an acceptable efficiency. This may be explained by the stronger pDNA binding 
ability of p(CBA-HIS). Finally, the cell viability experiment indicated that p(CBA-
HIS) polyplexes have a negligible cytotoxicity relative to LF complexes and as well 
as p(CBA-ABOL). 
All in all, p(CBA-HIS) is stated to form stable complexes in HEPES but not in the 
extracellular environment, have high uptake efficiency and good cell viability. The 
same strategies as for p(CBA-ABOL) polyplexes can be used to increase the stability 
of p(CBA-HIS) complexes in OptiMEM media and facilitate the transfection 
efficiency. 
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6.  CONCLUSION 
Gene therapy is the treatment of human diseases with an underlying genetic cause by 
delivering therapeutic genetic material (transgene) into the diseased cells of the 
patient. It has been a promising way to treat genetic diseases over the last decades 
because it offers a solution to treat the causes of diseases rather than curing the 
symptoms. 
In this project, pDMAEMA polymer/pDNA complexes were evaluated as an 
example of non-biodegradable polymers. These polyplexes were able to form stable 
complexes with pDNA and transfect the ARPE-19 cells with a moderate efficiency. 
Apart from lower gene expression, pDMAEMA polymer had a cytotoxic effect on 
ARPE-19 cells. 
Secondly, SS-PAAs were evaluated as an example of biodegradable and bioreducible 
polymer systems. Additionally different coating strategies and side chains were 
applied to improve the efficiency of these systems. All types of SS-PAA polymer 
were able to form stable complexes with pDNA. p(CBA-ABOL) was reported to a 
good transfection agent with relatively high cell viability however, its stability in the 
physiological mimicking media should be increased. PEGylation strategy was 
expected to increase the stability of p(CBA-ABOL) complexes and the positive 
effect was observed. Nevertheless, PEGylated polymers were not able to taken up by 
the ARPE-19 cells and transfect. HA-coating was an alternative way to increase the 
stability of particles and facilitate their uptake efficiency. The experiments resulted 
in expected way however, the effect of HA Mw on the transfection efficiency should 
be further investigated.  
Finally, p(CBA-HIS) was chosen to be evaluated in terms of cellular uptake and 
transfection. This polymer was supposed to have an increased transfection efficiency 
due to the buffering capacity and higher pKa of imidazole groups. The expected 
efficiency for transfection did not observed with p(CBA-HIS) polyplexes which their 
DNA release profile in the intracellular environment should be further analyzed. 
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 APPENDIX A  
Preliminary Study for HA-coated p(CBA-ABOL) Polyplexes 
Prior to the studies that were performed by research grade HA obtained from Life 
Core, the enzymatically degraded HA was evaluated. For this purpose the HA 
powder with unknown Mw was dissolved in water. Then the hyaluronan degradation 
enzyme hyaluronidase was dissolved in gelatin hydrolyzed and this enzyme solution 
was used to digest the HA by stirring overnight. Afterwards, the digested HA 
solution was filtered by ultrafilters with 30 kDa and 50 kDa molecular weight cut-off 
(MWCO) and centrifuged. Finally obtained HA was assumed to have a Mw of 30-50 
kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1 : Comparison of transfection efficiency of enzymatically degraded HA-
coated p(CBA-ABOL) polyplexes on ARPE-19 cells with LF and non-
coated p(CBA-ABOL) complexes. 
 
 
 
 
The next day of the seeding, freshly prepared HA-coated polymer/pDNA complexes 
were added to cells with a 2 µg concentration per well. For transfection experiments, 
gWiz-GFP plasmid was used. Then the average GFP expression of the total gated 
population of cells (pink bars) and the amount of GFP-positive cells (purple bars) 
were measured by flow cytometry. Non-treated cells and the cells which were 
transfected with non-fluorescent pGL4.13 plasmid were negative controls for 
transfection experiments. As a positive control, three wells were treated with 
lipoplexes formed by LF. p(CBA-ABOL) polyplexes were used as comparative 
reference. The measurements were carried out in triplicate and data are shown with 
standard deviation of three independent samples. 
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